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Abstract 1 
Background 2 
Atrial fibrillation (AF) is a highly prevalent disorder leading to heart failure, stroke, and death. Enhanced 3 
understanding of modifiable risk factors may yield opportunities for prevention. The risk of AF is increased in 4 
subclinical hyperthyroidism, but it is uncertain whether variations in thyroid function within the normal range 5 
or subclinical hypothyroidism are also associated with AF.  6 
 7 
Methods 8 
We conducted a systematic review and obtained individual participant data from prospective cohort studies 9 
that measured thyroid function at baseline and assessed incident AF. Studies were identified from MEDLINE 10 
and EMBASE databases from inception to July 27, 2016. The euthyroid state was defined as thyroid stimulating 11 
hormone (TSH) 0.45-4.49mIU/l, and subclinical hypothyroidism as TSH 4.5-19.9mIU/l with free thyroxine (fT4) 12 
levels within reference range. The association of TSH levels in the euthyroid and subclinical hypothyroid range 13 
with incident AF was examined using Cox proportional hazards models. In euthyroid participants, we 14 
additionally examined the association between fT4 levels and incident AF. 15 
 16 
Results 17 
Of 30,085 participants from 11 cohorts (278,955 person-years of follow-up), 1,958 (6.5%) had subclinical 18 
hypothyroidism, and 2,574 individuals (8.6%) developed AF during follow-up. TSH at baseline was not 19 
significantly associated with incident AF in euthyroid participants or those with subclinical hypothyroidism. 20 
Higher fT4 levels at baseline in euthyroid individuals were associated with increased AF risk in age- and sex-21 
adjusted analyses (hazard ratio=1.45; 95% confidence interval, 1.26-1.66, for the highest quartile vs the lowest 22 
quartile of fT4, p for trend ≤0.001 across quartiles). Estimates did not substantially differ after further 23 
adjustment for preexisting cardiovascular disease.  24 
 25 
Conclusion  26 
In euthyroid individuals, higher circulating fT4 levels, but not TSH levels, are associated with increased risk of 27 
incident AF.  28 
 29 
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Clinical Perspective 1 
What Is new? 2 
 Subclinical hyperthyroidism is associated with increased risk of atrial fibrillation, but the association 3 
with thyroid function in the normal range or subclinical hypothyroidism is unclear. 4 
 We performed an individual participant data analysis investigating the association between thyroid 5 
function within the normal range or subclinical hypothyroidism and the risk of atrial fibrillation, 6 
including more than 30,000 participants from 11 prospective cohort studies.  7 
 Our study showed that higher free thyroxine levels were associated with an increased risk of atrial 8 
fibrillation in euthyroid persons, whereas thyroid stimulating hormone levels were not. 9 
 10 
What Are the Clinical Implications? 11 
 Given the high prevalence of atrial fibrillation and its potentially disabling clinical outcomes, 12 
identification of modifiable risk factors is important. 13 
 Free thyroxine levels might add to further assessment of atrial fibrillation risk 14 
 Further studies need to investigate whether these findings apply to thyroxine-treated patients, who 15 
often have higher circulating free thyroxine levels than untreated participants, to assess whether 16 
treatment goals should be modified.  17 
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Introduction 1 
Atrial fibrillation (AF) affects more than 30 million individuals worldwide, and its prevalence and incidence is 2 
increasing globally.1 AF leads to significant morbidity and mortality,2 and increases the risk of stroke, heart 3 
failure, and subsequent hospitalizations.3 Identification of modifiable risk factors and potentially reversible 4 
causes is crucial for prevention and treatment of AF. Overt hyperthyroidism is a recognized risk factor for AF,4 5 
and measurement of thyroid function is recommended in the initial evaluation of patients with AF.5 Subclinical 6 
thyroid dysfunction, which is defined as abnormal thyroid stimulating hormone (TSH) levels with free thyroid 7 
hormone concentrations within the reference range, is common, with up to 9% of the adult population being 8 
affected by subclinical hypothyroidism and 2-3% by subclinical hyperthyroidism.6, 7 The risk of AF is increased in 9 
subclinical hyperthyroidism, especially when TSH levels are lower than 0.10mIU/l.8, 9 10 
Subclinical hypothyroidism increases the risk of cardiovascular events,10 but its association with incident AF risk 11 
remains uncertain.9, 11-13 Variations in thyroid hormone levels within the reference range have been associated 12 
with adverse cardiac events, and recent studies have suggested that higher free thyroxine (fT4) levels lead to 13 
an increased risk of heart failure and sudden cardiac death in euthyroid individuals.14, 15 Data from 14 
observational studies on the association between thyroid function within the reference range and the 15 
incidence of AF are conflicting.11, 16, 17 16 
Therefore, we aimed to examine the risk of AF in individuals with thyroid function within the normal range and 17 
subclinical hypothyroidism by performing an individual participant data (IPD) analysis of prospective cohort 18 
studies. An IPD analysis might help clarify the conflicting results of previous studies; it is considered the 19 
methodological gold-standard for summarizing evidence from observational studies and to analyze the impact 20 
of age, sex, and thyroid medication in subgroup analyses, as it is not affected by potential aggregation bias 21 
from study-level meta-analyses (ecological fallacy).18, 19 This approach allows also a uniform definition of 22 
thyroid function and adjustments of similar confounders with the aim of reducing heterogeneity across studies.23 
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Methods 1 
This IPD analysis was conducted according to the predefined protocol registered on PROSPERO (registration 2 
number CRD42016043906). Reporting conformed to the PRISMA-IPD statement.20 3 
Data Sources and Study Selection 4 
We conducted a systematic literature review of published articles in the MEDLINE and EMBASE databases, from 5 
inception to July 27, 2016, on the association between TSH and AF events, without language restriction 6 
(Supplemental Methods 1). We also performed a manual literature search, in which we reviewed expert papers 7 
in the field, screened bibliographies from retrieved articles, and requested data from cohorts participating in 8 
the Thyroid Studies Collaboration.8, 10, 21, 22 Predefined inclusion and exclusion criteria were used to improve 9 
comparability and quality of the studies. We included only full-text published longitudinal cohort studies that 10 
assessed thyroid function at baseline (serum TSH and fT4), and that had a euthyroid control group and 11 
prospective follow-up of AF events. We excluded studies that included only participants with overt thyroid 12 
dysfunction (abnormal TSH and fT4 levels), only participants that took thyroid-altering medications (anti-13 
thyroid drugs, thyroxine, or amiodarone), or that assessed only postoperative AF events. Two authors (C.B. and 14 
C.F.) independently screened references for eligibility; discrepancies were resolved in consultation with a third 15 
author (N.R.). Agreement between reviewers was 98.6% for first screening phase (titles and abstracts, kappa= 16 
0.66), and 95.0% for the second screening phase (full-text screen, kappa=0.83). 17 
Two authors (C.B. and C.F.) rated the methodological quality of the included studies based on individual criteria 18 
of the Newcastle-Ottawa Quality Assessment Scale (Supplemental Methods 2).23 19 
Institutional review boards approved all studies, and written informed consent was granted by all participants. 20 
The sponsors had no role in the design, analysis or reporting of the study.  21 
Data Extraction 22 
We contacted investigators from included studies and requested prespecified IPD on baseline thyroid function 23 
(TSH and fT4), demographic characteristics (age, sex, race), cardiovascular and AF risk factors (blood pressure, 24 
diabetes mellitus, total cholesterol, smoking), preexisting cardiovascular disease, history of AF, and medication 25 
use at baseline (thyroid-altering medications including thyroxine, anti-thyroid medication, lithium,  26 
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amiodarone, glucocorticoids, iodine, aspirin, furosemide; cardiovascular medications such as antihypertensive 1 
and lipid-lowering drugs) for each participant (see Supplemental Table 1 for definition of baseline covariates in 2 
the included studies). Data on AF outcomes were collected. We checked data for consistency and 3 
completeness, excluded unrealistic data points, and contacted authors of the cohorts to clarify variable 4 
definitions. For two studies for which authors could not share IPD (one cohort due to legal constraints,24 and 5 
another one9 due to prohibitive costs; Table 1), we looked for published aggregate data on the association 6 
between thyroid function and AF, so we could perform sensitivity analyses that included these studies. 7 
 Thyroid Function Testing 8 
In line with our previous analyses8, 10, 21 and based on an expert consensus meeting of the Thyroid Studies 9 
Collaboration (International Thyroid Conference, Paris, France, 2010), expert reviews,34, 35 and previous large 10 
cohorts,13, 36 we used uniform cutoff levels of TSH to define thyroid dysfunction and optimize the comparability 11 
of the included studies. Similar to previous studies, euthyroidism was defined as a TSH level from 0.45 to 12 
4.49mIU/L and further subdivided into five categories: 0.45-0.99mIU/l; 1.00-1.49mIU/l; 1.50-2.49mIU/l; 2.50-13 
3.49mIU/l; and 3.50-4.49mIU/l.37  14 
Subclinical hypothyroidism was defined as a TSH level between 4.5-19.9mIU/L with fT4 levels in the reference 15 
range, and was further subdivided into subclinical hypothyroidism with mildly elevated TSH 4.50-6.9mU/l, 16 
moderately elevated TSH 7.0-9.9mIU/l, and markedly elevated TSH 10.0-19.9mIU/l.10 In some cohorts, we also 17 
included participants with missing fT4 measurements and a TSH within the range for subclinical hypothyroidism 18 
in the main analyses (Table 2), because most people with TSH levels in this range have subclinical rather than 19 
overt thyroid dysfunction.7 We performed a sensitivity analysis, with exclusion of individuals with missing fT4 20 
values. 21 
Study-specific cut-offs were used for fT4 (Table 2) because intermethod variation is greater for these 22 
measurements than in TSH assays;10 participants were categorized in fT4 quartiles.  23 
We excluded those with overt thyroid dysfunction or thyroid hormone values that suggested non-thyroidal 24 
illness (low TSH and fT4 levels) or subclinical hyperthyroidism, as we have already published these results (this 25 
previous publication was based on a smaller number of studies, as new data became available since its 26 
publication in 2012).8 To restrict our analysis to patients with endogenous values of thyroid function, 27 
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participants on thyroid medication (thyroxine, anti-thyroid medication) at baseline were excluded 1 
(Supplemental Figure 1), while those initiating thyroid medications during follow-up were included in the  main 2 
analyses.8 Additional sensitivity analyses excluding users of thyroid medication during follow-up were 3 
performed. 4 
Outcomes 5 
The outcome was incident AF; participants with pre-existing AF at baseline were excluded from all analyses. 6 
The ascertainment of AF included electrocardiograms (ECG) during follow-up (9 studies), self-report, diagnostic 7 
codes, and review of medical records depending on the cohorts (Table 2). As AF ascertainment by self-report 8 
and review of medical records might be less specific, we performed a sensitivity analysis excluding studies with 9 
AF diagnosis without ECG review. Any type of AF (paroxysmal, persistent, permanent) was considered. 10 
Statistical Analyses 11 
Differences in baseline characteristics of participants with euthyroidism and those with subclinical 12 
hypothyroidism were compared using a chi-squared test or Student’s t-test, as appropriate. Crude incidence 13 
rates for AF per 1000 person-years were calculated using an inverse variance random-effects meta-analysis of 14 
log incidence rates, and point estimates and their 95% confidence intervals (CI) were exponentiated to obtain 15 
the incidence rates. An IPD analysis was conducted using a one-step approach.18 A Cox proportional hazard 16 
regression analysis using random-effects (shared-frailty) by cohort was used to describe the association 17 
between incident AF and TSH or fT4.38 The proportional hazards assumption was met. For the analysis with TSH 18 
as the explanatory variable, euthyroid participants within the TSH category from 3.50-4.49mIU/l were used as 19 
the reference group. The reference group was chosen according to the assumption of a S-shaped association 20 
between TSH and the risk of AF based on previous findings.11, 14 All TSH categories were analyzed in a single 21 
model. Following the recent publications of studies indicating an association between fT4 levels in the 22 
reference range and major adverse events including AF14, 24 and stroke,22 we also conducted a secondary 23 
analysis (not prespecified in the study protocol) of the association between fT4 in the euthyroid range and AF; 24 
study-specific quartiles of fT4 were computed, and the lowest fT4 quartile was the reference group. Only 25 
participants with both TSH and fT4 levels within the reference range were included in the secondary analysis.  26 
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The main analyses of both the association between TSH or fT4 and incidence of AF were adjusted for age and 1 
sex.10 In a following step, additional adjustment was done for traditional cardiovascular risk factors, including 2 
systolic blood pressure, current or former smoking, diabetes mellitus, total cholesterol and prevalent 3 
cardiovascular disease (multivariable adjusted analysis); as some of these risk factors might be mediators in the 4 
relationship between thyroid hormones and incidence of AF, the age- and sex-adjusted model was considered 5 
the main analysis. Whenever there was an indication of a linear association, we calculated p for linear trend for 6 
the main and multivariable adjusted analysis. Because data were not available in all cohorts, we also performed 7 
sensitivity analyses additionally adjusted for 1) antihypertensive and lipid-lowering medication and 2) body 8 
mass index. Additional sensitivity analyses 3) included all individuals regardless of intake of thyroid medication 9 
(thyroxine or anti-thyroid medication), so participants with thyroid medication use at baseline were added to 10 
this sensitivity analysis, 4) excluded participants who took amiodarone at baseline (or studies which did not 11 
provide this information), 5) excluded participants who took any other medications that might alter thyroid 12 
function (amiodarone, lithium, glucocorticoids, iodine, aspirin, furosemide) at baseline, 6) excluded those 13 
having received thyroid medication during follow-up (or studies that did not provide this information), 7) 14 
excluded studies in which no ECGs were used to diagnose AF, 8) excluded studies with >5% lost to follow-up, 15 
and 9) excluded a study that tested thyroid function an average of 3.4 years before incident AF was first 16 
assessed.26 For analyses of the association between TSH levels and the risk of AF, we also performed sensitivity 17 
analyses that 10) excluded participants whose fT4 measurements were missing, 11) were restricted to 18 
individuals with persistent thyroid function state, i.e. included only those with thyroid function measurements 19 
that remained in the same category (euthyroidism or subclinical hypothyroidism) during follow-up thyroid 20 
function testing, and 12) excluded a study29 conducted in a region where an iodine supplementation program 21 
was initiated a few years before the study was started, leading to a shift of TSH values towards lower levels in 22 
this population during the baseline examination.39 All sensitivity analyses were prespecified in our protocol, 23 
with the exception of 4), 9), 11), and 12).  24 
To examine potential sources of heterogeneity, we conducted predefined subgroup analyses similar to those in 25 
our previous studies,8, 10 which considered age, sex, race, the prevalence of cardiovascular disease. In an 26 
additional analysis, individuals with thyroxine use at baseline were included and a subgroup analysis stratified 27 
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on thyroxine use at baseline was performed. P-values to test for interaction in the subgroup analyses were 1 
derived from Wald tests.  2 
We analyzed the association between continuous concentrations of TSH or fT4 and AF. For the association 3 
between TSH and AF, a 4-knot restricted cubic spline was used with knots at TSH levels of 1.0mIU/l, 2.5mIU/l, 4 
4.5mIU/l, and 10mIU/l, to represent three categories within the reference TSH range, as well as categories of 5 
subclinical hypothyroidism with mild to moderately elevated TSH and markedly elevated TSH levels.10 Hazard 6 
ratios were compared to a reference value of 3.5mIU/l, according to the lower bound of the cut-off used for 7 
our reference category. For the association between continuous concentrations of fT4 within the reference 8 
range and AF, we expressed fT4 in standard deviation units centered around the mean to make fT4 values 9 
comparable across studies. For this analysis, we used a 1-knot restricted cubic spline with the knot placed at 10 
the median value of fT4 in standard deviation units, which resulted in the best model fit. Spline regression 11 
analyses were adjusted for age and sex. We calculated a p for non-linear trend using a likelihood ratio test 12 
comparing the models with and without the TSH or fT4 splines, respectively. This analysis was not prespecified 13 
in our protocol. Statistical significance was tested two-sided and p-values <0.05 were judged significant. We 14 
used inverse variance random-effects meta-analysis to combine the summary estimates of our IPD analysis 15 
with results from two studies that provided only aggregate data. We used a funnel plot to assess for potential 16 
publication bias of the association between fT4 levels within the reference range and the risk of AF, considering 17 
the estimates of the highest quartile of fT4 compared to the lowest quartile. All analyses were conducted using 18 
Stata version 14.1 (StataCorp. 2015. College Station, TX: StataCorp LP). 19 
 20 
21 
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Results 1 
Of the 1,418 identified reports, 14 prospective studies met our eligibility criteria (Supplemental Figure 2 and 2 
Supplemental Table 2). Among those, 6 studies9, 13, 14, 16, 24, 31 were published and 8 cohorts25-30, 32, 33 offered 3 
previously unpublished data. As two of the studies included the same population, we contacted 13 cohorts and 4 
asked them to share IPD. Of these, 11 international cohorts (from Europe, the United States and Australia) 5 
agreed to provide IPD and we added summary estimates of 2 studies that did not provide IPD in random-6 
effects models as sensitivity analyses.  7 
After exclusion of participants with thyroxine and anti-thyroid medication use at baseline, 30,085 individuals 8 
were included in the final analysis (Supplemental Figure 1). Among included participants, median age was 69 9 
years at inclusion, 51.6% were women, 28,127 individuals were euthyroid, and 1,958 (6.5%) had endogenous 10 
subclinical hypothyroidism. Median follow-up ranged from 1.3 to 17 years across the different studies, adding 11 
up to 278,955 person-years of follow-up; during this time, 2,574 individuals (8.6%) developed incident AF. 12 
Thyroid medication use (thyroxine and anti-thyroid medication) during follow-up varied from 1.2-11.2% in the 13 
various studies (Table 1). Compared to participants with euthyroidism, those with subclinical hypothyroidism 14 
were older, more likely to be female or affected by comorbidities including cardiovascular disease or diabetes 15 
(Supplemental Table 3).  16 
Overall study quality was high; all included studies scored 6 points or higher on the Newcastle-Ottawa Quality 17 
Assessment Scale. All cohorts were community-based, and two27, 32 cohorts did not use ECG review to diagnose 18 
AF. Length of follow-up was more than five years, except for two studies,27, 31 and loss of follow-up was lower 19 
than 5% in 6 studies (Supplemental Table 4).  20 
Thyroid stimulating hormone within the Reference Range and the Risk of Atrial Fibrillation 21 
Crude incidence rates are presented in Figure 1. In age- and sex-adjusted analyses, there was no association 22 
between TSH levels in the reference range and risk of AF (Figure 1). When analyzing continuous concentrations 23 
of TSH, the risk of AF increased with low normal TSH levels and slightly decreased with higher TSH levels (but 24 
remaining close to a hazard ratio [HR] of 1.0) compared to the reference level of 3.5mIU/l (Supplemental Figure 25 
3). Sensitivity analyses yielded similar results (Table 3 and Supplemental Table 5), and no significant interaction 26 
13 
 
was found when analyses were stratified according to sex, age, or previous cardiovascular disease. In the 1 
analysis with additional inclusion of individuals with thyroxine use at baseline, point estimates were higher 2 
among thyroxine users than among those not on thyroxine in a subgroup analysis, however without statistical 3 
significance likely because of the limited number of thyroxine users (n=1146, Supplemental Table 6).  4 
Subclinical Hypothyroidism and the Risk of Atrial Fibrillation 5 
Compared to the reference level of 3.50-4.49mIU/l, subclinical hypothyroidism was not associated with 6 
incident AF in age- and sex-adjusted analyses, with a HR of 0.92 (95% confidence interval [CI], 0.74-1.14) for a 7 
TSH level of 4.5-6.9mIU/l, a HR of 1.02 (95% CI, 0.73-1.41) for a TSH level of 7.0-9.9mIU/l, and a HR of 0.94 (95% 8 
CI, 0.61-1.47) for a TSH level of 10.0-19.9mIU/l (Table 4). The results remained similar in sensitivity analyses 9 
(Table 4 and Supplemental Table 7), and analyses stratified by sex, age, previous cardiovascular disease, and 10 
thyroxine use at baseline showed no significant interaction (Supplemental Table 8). Adding overall relative risks 11 
(HRs not reported) of one study from which we were not able to obtain IPD9 yielded similar results for the 12 
association between subclinical hypothyroidism and AF (HR was 1.07, 95% CI, 0.72-1.58).  13 
Free Thyroxine within the Reference Range and the Risk of Atrial Fibrillation 14 
Crude incidence rates are shown in Figure 2. Among the 30,085 individuals included in our study, 20,921 were 15 
included in the analysis of the association between fT4 and AF, having both their TSH and fT4 within the 16 
reference range. In those individuals, higher fT4 levels at baseline were associated with increased risk of AF in 17 
age- and sex-adjusted analyses, with a HR of 1.17 (95% CI, 1.02-1.35) in the second quartile, a HR of 1.25 (95% 18 
CI, 1.09-1.43) in the third, and a HR of 1.45 (95% CI, 1.26-1.66) in the fourth quartile compared to the first 19 
(lowest) quartile of fT4 levels (p for trend across fT4 levels ≤0.001) (Figure 2). When modeled as a continuous 20 
variable, increasing fT4 levels within the reference range were associated with an increased risk of AF 21 
(Supplemental Figure 4). In analyses with multivariable adjustment for age, sex, systolic blood pressure, 22 
smoking, diabetes, total cholesterol, and prevalent cardiovascular disease at baseline, HRs remained similar. 23 
Further adjustments for antihypertensive, lipid lowering medication, and BMI did not significantly change the 24 
results. Sensitivity analyses yielded similar results (Table 5 and Supplemental Table 9). Risks were similar when 25 
all individuals regardless of thyroid medication use at baseline were included, or after excluding studies 26 
without AF diagnosis by ECG review,27, 32 or when excluding a study26 that started follow-up of incident AF an 27 
14 
 
average of 3.4 years after baseline thyroid function was measured. Estimates did not change substantially after 1 
we added the aggregate results from a study that did not provide IPD.24 2 
Stratified results are presented in Figure 3 and Supplemental Table 10. Compared to those without known 3 
cardiovascular disease, participants with previous cardiovascular disease showed no association between fT4 4 
levels and AF risk. However, this finding might be affected by selection bias due to exclusion of participants 5 
with prevalent AF at baseline. Risks did not differ substantially according to age, sex, and race. In an additional 6 
analysis including thyroxine users, risks were similar irrespective of thyroxine intake at baseline.  7 
Assessment of Potential Publication Bias 8 
Visual inspection of the funnel plot did not suggest publication bias for the association between fT4 within the 9 
reference range and the risk of AF (Supplemental Figure 5).   10 
15 
 
Discussion 1 
Our IPD analysis including 30,085 individuals from 11 prospective cohorts showed no association between TSH 2 
levels within the reference range or subclinical hypothyroidism and risk of AF. In euthyroid individuals, we 3 
found a significant increase in the risk of AF with increasing fT4 levels within the reference range. Risks did not 4 
differ significantly by age and sex. 5 
To our knowledge, our study is the first IPD analysis of prospective cohorts on the association between thyroid 6 
function in the reference range or subclinical hypothyroidism and the risk of AF. Our study was strengthened by 7 
its large sample size, which allowed us to assess risks in subgroups by TSH levels in the normal range. 8 
Furthermore, our results were robust across all sensitivity analyses. By conducting an IPD analysis, our results 9 
are free of potential aggregation bias found in study-level meta-analyses,18 and we could explore the impact of 10 
age, sex, and thyroid medication in subgroup analyses. This approach also enabled us to standardize definitions 11 
of predictors and outcomes, use uniform adjustments for potential confounders to reduce heterogeneity 12 
across studies, and include unpublished data to increase robustness of our results and power to detect 13 
associations. IPD analyses are the ideal approach to aggregating evidence by pooling estimates from multiple 14 
studies.19 15 
Our study confirmed previous results from two recent prospective population-based studies that found an 16 
increased risk of AF in higher fT4 levels in euthyroid individuals, while TSH levels were not associated with AF.14, 17 
24 Similar results were shown in a cross-sectional study that included older adults.17 Recently, a large Danish 18 
retrospective register study of more than half a million individuals found a linear increase in risk of incident AF 19 
with decreasing TSH levels, resulting in a protective effect of subclinical hypothyroidism on AF compared to the 20 
euthyroid state. Participants in the high-normal euthyroidism subgroup defined as TSH of 0.2-0.4mIU/l with 21 
thyroxine levels in the reference range had a higher AF risk (incident rate ratio 1.12, 95% CI, 1.03-1.21) 22 
compared to low normal euthyroidism, defined as TSH 0.4-5.0mIU/l.11 However, the investigators chose 23 
different TSH cut-off values than used in our and other studies,8, 9, 13, 16, 17 and defined the TSH range 0.2-24 
0.4mU/l as high normal euthyroidism (which was defined as subclinical hyperthyroidism in our study); strictly 25 
speaking, risk of AF within the euthyroid range with a TSH of 0.4-5.0mU/l has not been investigated. In contrast 26 
to the Danish study, we identified no significant association between subclinical hypothyroidism with AF, but 27 
our results showed a similar trend across higher TSH levels. However, the Danish study was based on 28 
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retrospective administrative data, which has inherent drawbacks, including potential confounding by indication 1 
(TSH was not randomly ordered by general practitioners) and no ECG confirmation of AF. In contrast, the 2 
results of the Framingham Heart Study aligned with ours, where no association between TSH levels above the 3 
reference range and the risk of AF was found among 5069 participants during a 10-year follow up.12 4 
Thyroxine is one of the most frequently prescribed drugs in the United States (almost 120 million prescriptions 5 
are dispensed annually)40 and prescriptions continue to rise, even for individuals with TSH levels below 6 
10mIU/l.41 Although our primary analyses focused on endogenous thyroid function, we also examined 7 
thyroxine users in stratified analyses. These results remained consistent with higher AF risk with increasing FT4 8 
levels; our data also showed that the majority of thyroxine users had a fT4 level in the highest quartile. 9 
However, the subgroup of individuals on thyroid replacement therapy at baseline was comparatively small in 10 
our study (n=1146), which precludes a meaningful interpretation of the AF risk associated with thyroxine 11 
therapy. Further studies are needed to evaluate whether our findings apply to this subgroup.  12 
Our study has several limitations. First, we did not pre-specify our analysis of the association between fT4 and 13 
AF risk in the protocol; because two prospective cohorts, published after we completed our protocol, found a 14 
significant association between fT4 in the euthyroid range and incident AF,14, 24 we decided to explore AF risk 15 
according to fT4 levels. Our robust results have confirmed these previous findings. Second, AF can be 16 
paroxysmal or asymptomatic, and real incident date for AF might have been missed in the cohorts that 17 
diagnosed AF solely by ECG review during study visits. Therefore, we might have substantially underestimated 18 
the true incidence of AF in our study and introduced non-differential misclassification of outcomes, which 19 
would result in an underestimation of the association. Third, only five of the included studies provided data on 20 
follow-up thyroid function measurements, so data on the evolution of thyroid function over time was limited, 21 
which applies to most published large cohorts.13, 16, 25 This limitation mainly affects the analysis of individuals 22 
with subclinical hypothyroidism, who might reverse to normal thyroid function or progress to overt thyroid 23 
dysfunction. However, a sensitivity analysis including only participants with persistent thyroid function during 24 
follow-up thyroid function measurements yielded similar estimates. Fourth, despite the large number of 25 
individuals we included in our analysis, important subgroups of interest (such as participants with high TSH 26 
levels or individuals on thyroxine therapy at baseline) were small, and analyses restricted to these subgroups 27 
were underpowered. Fifth, we could not obtain IPD from two studies that met our inclusion criteria. Therefore, 28 
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we performed sensitivity analyses adding the published aggregate results from these two studies,9, 24 which 1 
yielded similar results. We could not add the aggregate results of the association between TSH in the reference 2 
range and AF published in the study by Chaker and colleagues, because they used different TSH cut-offs by 3 
subdividing TSH into quartiles.24 Sixth, we were not able to include time-updated variables in our analyses due 4 
to limited availability. Seventh, the definition of some of the baseline covariates including cardiovascular 5 
disease and diabetes mellitus were heterogeneous across different cohorts. Finally, our study included mainly 6 
Caucasians and younger participants were few (median age 69 years), which reduces the generalizability of our 7 
findings to other populations.  8 
The mechanism for the association between thyroid function and AF may be explained by the effects of thyroid 9 
hormones on the cardiovascular system. Thyroid function in the high range leads to an increase in vascular 10 
resistance, cardiac contractility, heart rate and left ventricular mass.42 Thyroid hormone levels in the high range 11 
have been shown to be arrhythmogenic43 and increase the frequency of atrial premature beats,44 which in turn 12 
is a risk factor for AF.45 These effects may explain the observation of an increased risk of AF in subclinical 13 
hyperthyroidism8 but not subclinical hypothyroidism. Due to the negative feedback, a negative log-linear 14 
relationship exists between fT4 and TSH with disproportionately larger changes in TSH concentrations than 15 
those of fT4.46 Therefore, TSH would be expected to be more sensitive than fT4 to predict outcomes. However, 16 
circulating fT4 is peripherally converted to the biologically active triiodothyronine, which binds on nuclear 17 
receptors and mediates gene expression with consecutive effects on end-organs, whereas TSH is a marker of 18 
pituitary effects of thyroid function.47 In contrast to the positive association between fT4 and AF, we did not 19 
find an association between TSH levels in the reference range and AF, and this pattern of a positive association 20 
between fT4 but not TSH values in the reference range has also been shown for other adverse cardiac 21 
outcomes including congestive heart failure14 and sudden cardiac death,15 as well as for blood pressure.48 22 
These results of the effect of normal thyroid function on the heart are in contrast to the findings of a 23 
statistically significant inverse association between TSH levels within the reference range and dementia, 24 
whereas no significant association between fT4 levels in the normal range and rates of dementia was found in 25 
this study,14 suggesting that thyroid hormone metabolism and action differs between target organs such as the 26 
heart and brain because of differences in deiodinase activity and thyroid hormone receptor expression;47 these 27 
differences may explain why some clinical phenotypes are associated with fT4 only, some with TSH only, and 28 
18 
 
others with both. These findings are also consistent with the observation that fT4 concentrations may differ 1 
even among euthyroid persons with the same TSH values:49 individuals with higher fT4 values have higher 2 
cardiac exposure to thyroid hormones and are consecutively at a higher risk of AF, which is reflected by the 3 
findings of our study. Levels of fT4 might be an additive risk factor for adverse cardiac outcomes; however, 4 
before making recommendations for fT4 screening in euthyroid individuals, further (ideally randomized) 5 
studies are needed to assess benefits and harms of fT4 screening.   6 
In conclusion, our IPD analysis of prospective cohorts showed that fT4 levels within the high-normal range were 7 
associated with increased risk of incident AF, but incident AF events did not increase across TSH categories 8 
within the euthyroid range or in subclinical hypothyroidism. Further studies are needed to investigate whether 9 
these results apply to thyroxine users, which might entail a careful evaluation of the risks and benefits of 10 
current target thyroid hormone concentrations for thyroid replacement therapy. 11 
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Figure Legend 1 
 2 
Figure 1. Association between thyroid stimulating hormone and the risk of atrial fibrillation. Participants who 3 
used thyroid hormones at baseline were excluded. CI, confidence interval; p-y, person-years; TSH, thyroid 4 
stimulating hormone. 5 
 6 
Figure 2. Association between quartiles of free thyroxine within the reference range and the risk of atrial 7 
fibrillation. The reference range for TSH was defined as 0.45-4.49mIU/l. For fT4, we used study-specific cutoff 8 
values. Participants who used thyroid hormones at baseline were excluded. CI, confidence interval; fT4, free 9 
thyroxine; p-y, person-years; TSH, thyroid stimulating hormone. 10 
 11 
Figure 3. Stratified analyses for the association between quartiles of free thyroxine within the reference range 12 
and risk of atrial fibrillation. We defined the reference range for TSH as 0.45-4.49mIU/l and used study-specific 13 
cutoff values for fT4; the first fT4 quartile was the lowest one. The p for trend refers to a linear trend. CI, 14 
confidence interval; fT4, free thyroxine, TSH, thyroid stimulating hormone. 15 
* Previous cardiovascular disease was defined as a history of stroke, transient ischemic attack, myocardial 16 
infarction, angina pectoris, coronary angioplasty, or bypass surgery.  17 
† 542 participants with available fT4 measurements and normal thyroid function were on thyroxine at baseline: 18 
167 participants in the CHS; 33 in the MrO2; 6 in the Bari; 5 in the Leiden 85+ Study; 76 in SHIP; 11 in the 19 
InChianti Study; 9 in the Rotterdam Study; 8 in the PROSPER Study; 224 in the EPIC-Norfolk Study; and, 3 in the 20 
Busselton Health Study. 21 
 22 
 23 
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 Table 1. Study Characteristics  
 
 
Study 
  
Description of Study 
Sample 
 No. * 
  
Age, 
Median 
(Range), 
y † 
Women, 
No. (%) 
Cardio-
vascular 
Disease,  
No. (%) ‡ 
Endogenous 
Subclinical 
Hypo-
thyroidism, 
No. (%) § 
Medication Users during 
Follow-up, No. (%)|| 
Follow-up # 
Thyroxine Anti-
thyroid 
medication 
Start, y Duration, 
Median  
(IQR), y 
Person-
Years 
AF 
events, 
No. (%) 
United States             
Cardiovascular 
Health Study13 
Community-dwelling 
adults with Medicare 
eligibility in 4 US 
communities 
3,328 73  
(64-98) 
1917 
(57.6) 
845 
(25.4) 
436 (13.1) 308 (9.5) NA 1994-
1995 
11.7  
(7.0-18.1) 
32,632 886 
(26.6) 
Health ABC 
Study25 
Community-dwelling 
adults with Medicare 
eligibility in 2 US 
communities 
2,346 74  
(69-81) 
1143 
(48.7) 
625 
(27.1) 
270 (11.5) 114 (4.9) 2 (0.1) 1997 8.1  
(7.4-8.3) 
16,155 201 
(8.6) 
Osteoporotic 
Fractures in 
Men (MrOS) 
Study26 
Community-dwelling 
men aged 65 years or 
older in 6 US clinical 
centers 
678 72  
(65-91) 
0 135 
(19.9) 
45 (6.6) 18 (2.7) 0  2000-
2002 
12.6  
(11.2-13.1) 
7,668 62 (9.1) 
Europe             
Bari Study27 Outpatients with heart 
failure followed up by 
Cardiology Department 
in Bari, Italy 
268 65  
(21-92) 
55 (20.5) 103 
(38.4) 
23 (8.6) 22 (8.2) 8 (3.0) 2006-
2008 
1.3  
(0.6-1.9) 
339 14 (5.2) 
Leiden 85-plus 
Study28 
All adults aged 85 years 
living in Leiden, the 
Netherlands 
432 85  
(85-85) 
281 
(65.1%) 
166 
(38.4) 
27 (6.3) 5 (1.2) 3 (0.7) 1997-
1999 
5.5  
(2.7-9.0) 
1,575 44 
(10.2) 
SHIP29 ** Adults living in Western 
Pomerania, Germany 
2,339 45  
(20-85) 
1191 
(50.9) 
100 (4.3) 12 (0.5) 172 (7.4) 8 (0.3) 1997-
2001 
11.5  
(11.1-12.1) 
22,006 40 (1.7) 
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InChianti 
Study30 
Community-dwelling 
adults aged 65 years or 
older living in Tuscany, 
Italy 
1,051 71  
(21-103) 
581 
(55.3) 
123 
(11.7) 
26 (2.5) 17 (1.6) 2 (0.2) 1998 9.0  
(8.3-9.2) 
8,453 14 (1.3) 
Rotterdam 
Study16 
Inhabitants of Ommoord 
(The Netherlands) aged 
 55 years 
1,607  68  
(55-93) 
975 
(60.7) 
412 
(25.6) 
91 (5.7) NA NA 1990-
1993 
15.5  
(11.4-16.9) 
20,892 226 
(14.1) 
PROSPER 
Study31 
Community-dwelling 
elderly with high 
cardiovascular risk in 
The Netherlands, 
Scotland and Ireland 
5,334 74  
(69-83) 
2,645 
(49.6) 
2,356 
(44.2) 
384 (7.2) 57 (1.1) 11 (0.2) 1997-
1999 
3.3  
(3.0-3.5) 
16,529 496 
(9.3) 
EPIC-Norfolk 
Study32 
Adults aged 40 to 79 
years living in Norfolk, 
England 
11,642 58  
(39-78) 
6,181 
(53.1) 
442 (3.8) 607 (5.2) NA NA 1995-
1998 
17.0  
(16.1-18.0) 
137,861 575 
(4.9) 
Australia             
Busselton 
Health Study33 
Adults living in 
Busselton, Western 
Australia 
1,060 46  
(18-81) 
539 
(50.9) 
54 (5.1) 37 (3.5) 20 (1.9) 1 (0.1) 1981 14.0  
(14.0-14.0) 
14,840 16 (1.5) 
Overall 11 Cohorts 30,085 69  
(18-103) 
15,508 
(51.6)  
5,371 
(17.9) 
1,958 (6.5)  733 (2.4)  35 (0.1) 1981-
2008 
16.6  
(10.7-18.7) 
278,955 2,574 
(8.6) 
Studies where 
IPD were not 
available 
            
Framingham 
Heart Study9 
Adults aged  60 years 
from Framingham, USA 
1,759 
†† 
 60 (NA) 1037 
(59.0) 
NA 183 (10.4) NA NA 1978-
1980 
10.0 (NA) NA 156 
(8.9) 
Rotterdam 
Study Cohorts 
I, II and III24 ‡‡ 
Adults aged  55 years 
for Cohort II and  45 
years for Cohort III from 
Ommoord, The 
Netherlands 
8,740 63  
(45-105) 
5010 
(57.3) 
NA 722 (8.3) NA NA 2000-
2001  
Cohort II, 
2006-
2008 
Cohort III 
6.8 (3.9-
10.9) 
61,935 403 
(4.6) 
    
30 
 
Abbreviations: AF, atrial fibrillation; EPIC, European Prospective Investigation of Cancer; Health ABC Study, Health Aging and Body Composition Study; InChianti, 
Invecchiare in Chianti; IPD, individual participant data; IQR, Interquartile Range (25th-75th percentiles); NA, Data not Available; PROSPER, Prospective Study of Pravastatin 
in the Elderly at Risk; SHIP, Study of Health in Pomerania; TSH, thyroid stimulating hormone; y, Years   
*  We excluded from our analyses participants with prevalent atrial fibrillation at baseline, missing outcomes for atrial fibrillation, subclinical hyperthyroidism and overt 
thyroid dysfunction, and intake of thyroxine or antithyroid medication at baseline. 
† We excluded participants younger than 18 years. 
‡ Cardiovascular disease at baseline was defined as known history of stroke, transient ischemic attack, myocardial infarction, angina pectoris, coronary angioplasty, or 
bypass surgery. 
§ We used a common definition of subclinical hypothyroidism, TSH 4.5 mIU/L to 19.9mIU/L and normal free thyroxine level, but TSH cutoff values varied among the 
previous reports from each cohort, so numbers are different than in the original articles. To analyze only endogenous subclinical hypothyroidism, we excluded 253 
participants in the Cardiovascular Health Study, 207 in the Health ABC Study, 43 in the Osteoporotic Fractures in Men Study, 15 in the Bari study, 12 in the Leiden 85+ 
study, 107 in the Study of Health in Pomerania, 21 in the Invecchiare in Chianti Study, 26 in the Rotterdam study, 188 in the PROSPER study, 301 in the EPIC-Norfolk study, 
and 4 in the Busselton Health study because they used thyroid medication at baseline. 
|| We had no data on thyroid medication use during follow-up for 481 participants in the Study of Health in Pomerania, and all participants in the EPIC-Norfolk and the 
Rotterdam study. 91 participants in the Cardiovascular Health Study did not have information on thyroxin during follow-up, and information on antithyroid medication 
during follow-up was missing for all patients of the Cardiovascular Health Study. 5 persons took both thyroxine and anti-thyroid medication during the course of follow-up. 
# For all cohorts, we used the maximal follow-up data that were available, which may differ from previous reports of some cohorts. For the Cardiovascular Health Study, we 
set the baseline for our analysis to the year 5 visit of the original cohort because free thyroxine was measured at the year 5 visit. 
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** SHIP includes participants from Pomerania, where an iodine supplementation program began in the mid-1990s. This shifted the distribution of TSH values towards the 
left in its first years, which lowered TSH values in the population of the SHIP Study during baseline examinations in 1997-2001. 
†† Number of participants with euthyroidism and subclinical hypothyroidism. Participants with subclinical hyperthyroidism are not listed here, since they were not included 
in our sensitivity analysis or in the aggregate data from this cohort. 
‡‡ Data on characteristics of 8740 participants included in the longitudinal analysis by Chaker et al.24 was obtained through contact with the authors. Individual participant 
data of 1,602 participants was available for Rotterdam Study Cohort I (see above).  
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Table 2. Definition of Subclinical Hypothyroidism and Atrial Fibrillation Events 
Study Cohort TSH and fT4 
Reference Range 
Definition of Subclinical Hypothyroidism in IPD Analysis AF Events – Methods of Ascertainment 
United States    
Cardiovascular Health 
Study 
TSH 0.45-4.50 mIU/L,  
fT4 9-22 pmol/L 
TSH ≥4.5 mIU/L & TSH <20mIU/L, normal fT4 0.7-1.7 
ng/dL (9-22 pmol/L) or missing fT4 (0/436, 0%) 
Self-report, annual ECGs, ICD-9 coded AF on hospital discharge 
Health ABC Study TSH 0.1-4.4 mIU/L, 
fT4 10.3-23.2 pmol/L 
TSH ≥4.5 mIU/L & TSH <20mIU/L, normal fT4 0.8-1.8 
ng/dL (10.3-23.2 pmol/L) or missing fT4 (195/270, 72%) * 
Minnesota-coded ECGs at baseline and at year 4 follow-up, ICD-
9 coded ambulatory and inpatient AF diagnoses from CMS data  
Osteoporotic Fractures 
in Men (MrOS) Study 
TSH 0.55-4.78 mIU/L,  
fT4 9-24 pmol/L 
TSH ≥4.5 mIU/L & TSH <20mIU/L, normal fT4 0.7-
1.85ng/dL (9-24pmol/L) or missing fT4 (0/46, 0%) 
ECG at baseline, self-report, AF diagnoses from medical records 
every 4 months 
Europe    
Bari Study TSH 0.35-5.50 mIU/L,  
fT4 9-23.2 pmol/L 
TSH ≥4.5 mIU/L & TSH <20mIU/L, normal FT4 0.7-1.8 
ng/dL (9-23.2 pmol/L) or missing fT4 (0/23, 0%) 
ICD-9 coded AF on hospital discharge 
Leiden 85+ Study TSH 0.3-4.8 mIU/L,  
fT4 13-23 pmol/L 
TSH ≥4.5 mIU/L & TSH <20mIU/L, normal fT4 1.0-1.8ng/dL 
(13-23 pmol/L) or missing fT4 (1/27, 3.7%) 
Minnesota-coded annual ECGs 
Study of Health in 
Pomerania 
TSH 0.25-2.12 mIU/L,  
fT4 8.3-18.9 pmol/L 
TSH ≥4.5 mIU/L & TSH <20mIU/L, normal fT4 0.64-
1.47ng/dL (8.3-18.9 pmol/L) or missing fT4 (0/12, 0%) 
Minnesota-coded ECGs at baseline, year 5 and year 10 follow-up 
Invecchiare in Chianti 
Study 
TSH 0.46-4.68 mIU/l,  
fT4 9.9-28.2 pmol/L 
TSH ≥4.5 mIU/L & TSH <20mIU/L, normal fT4 0.77-
2.19ng/dL (9.9-28.2pmol/L) or missing fT4 (0/26, 0%) 
ECGs at baseline, 3 year, 6 year and 9 year follow-up 
Rotterdam Study  TSH 0.4-4.0 mIU/L,  
fT4 11-25 pmol/L 
TSH ≥4.5 mIU/L & TSH <20mIU/L, normal fT4 0.9-1.9ng/dL 
(11-25pmol/L) or missing fT4 (29/91, 31.9%) 
ECGs at baseline, year 2 and year 7 follow-up, ICD-10 coded AF 
diagnoses from GP records and hospital discharge 
PROSPER Study TSH 0.45-4.50 mIU/L,  
fT4 12-18 pmol/L 
TSH ≥4.5 mIU/L & TSH <20mIU/L, normal fT4 0.9-1.4 
ng/dL (12-18pmol/L) or missing fT4 (211/384, 54.9%) † 
Minnesota-coded annual ECGs 
EPIC-Norfolk  TSH 0.4-4.0 mIU/L,  
fT4 9-20 pmol/L 
TSH ≥4.5 mIU/L & TSH <20mIU/L, normal fT4 0.7-1.6ng/dL 
(9-20 pmol/L) or missing fT4 (0/607, 0%) 
Self reported intake of drugs used for AF treatment at baseline 
(digitalis and VKAs), ICD-10 coded AF on hospital discharge  
Australia    
Busselton Health 
Study 
TSH 0.4-4.0 mIU/L,  
fT4 9-23 pmol/L 
TSH ≥4.5 mIU/L & TSH <20mIU/L, normal fT4 0.7-1.8ng/dL 
(9-23 pmol/L) or missing fT4 (1/ 37, 2.7%) 
Minnesota-coded ECGs at baseline and at year 14 follow-up 
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Abbreviations: AF, atrial fibrillation; ECG, electrocardiogram; EPIC, European Prospective Investigation of Cancer; fT4, free thyroxine; GP, general practitioner; ICD, 
International Statistical Classification of Diseases and Related Health Problems; IPD, individual participant data; PROSPER, Prospective Study of Pravastatin in the Elderly at 
Risk; TSH, thyroid stimulating hormone, VKA, vitamin K antagonist. 
* fT4 was measured only in participants with TSH  7.0 mIU/L or TSH in this cohort  
† fT4 was measured only in participants with TSH 4.5mIU/l in this cohort 
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Table 3. Main and Sensitivity Analysis of the Association between Thyroid Stimulating Hormone within the Reference Range and the Risk of Atrial Fibrillation 
TSH level (mlU/l) 0.45-0.99  1.00-1.49  1.50-2.49  2.50-3.49  3.50-4.49  
 
Events / 
Persons 
HR 
(95% CI) 
Events / 
Persons 
HR 
(95% CI) 
Events / 
Persons 
HR 
(95% CI) 
Events / 
Persons 
HR 
(95% CI) 
Events / 
Persons 
HR 
(95% CI) 
All available cohorts           
Age- and sex-adjusted 372/5665 
1.10 
(0.92-1.31) 
492/6275 
1.03 
(0.87-1.22) 
893/9990 
1.04 
(0.89-1.22) 
412/4391 
0.94 
(0.79-1.12) 
190/1806 ref. 
Multivariable adjusted analysis* 370/5611 
1.07 
(0.89-1.28) 
487/6199 
0.99 
(0.84-1.18) 
882/9841 
1.02 
(0.87-1.19) 
410/4336 
0.92 
(0.78-1.10) 
187/1777 ref. 
Further adjustments of multivariable models*          
Plus antihypertensive and 
lipid lowering medication 
357/4924 
1.06 
(0.88-1.27) 
469/5699 
0.98 
(0.83-1.17) 
862/9297 
1.01 
(0.86-1.19) 
405/4138 
0.94 
(0.78-1.12) 
180/1703 ref. 
Plus BMI 356/4911 
1.07 
(0.89-1.29) 
466/5682 
0.99 
(0.84-1.18) 
855/9257 
1.02 
(0.87-1.20) 
403/4120 
0.94 
(0.79-1.13) 
179/1696 ref. 
Medication affecting thyroid function  
     
    
Including all regardless of thyroid 
medication use † 
399/5920 
1.10 
(0.92-1.31) 
516/6437 
1.05 
(0.89-1.24) 
925/10226 
1.06 
(0.91-1.23) 
432/4533 
0.96 
(0.81-1.14) 
200/1914 ref. 
Excluding thyroid medication use  
at BL and/or FUP ‡ 
370/5552 
1.10 
(0.91-1.32) 
483/6217 
1.01 
(0.85-1.21) 
881/9902 
1.04 
(0.88-1.22) 
393/4305 
0.93 
(0.78-1.11) 
173/1722 ref. 
Excluding users of amiodarone § 367/5639 
1.09 
(0.91-1.30) 
490/6254 
1.03 
(0.87-1.21) 
889/9958 
1.04 
(0.89-1.22) 
408/4380 
0.94 
(0.78-1.11) 
190/1795 ref. 
Excluding users of other drugs 
affecting thyroid function || 
241/4536 
1.21 
(0.96-1.53) 
302/4815 
1.12 
(0.89-1.40) 
531/7364 
1.13 
(0.91-1.40) 
222/3059 
0.99 
(0.78-1.25) 
103/1273 ref. 
Thyroid function 
Excluding participants with 
missing values of fT4 # 
288/4808 
1.10 
(0.89-1.34) 
365/4983 
1.01 
(0.83-1.22) 
650/7561 
1.01 
(0.85-1.21) 
289/3097 
0.90 
(0.74-1.10) 
147/1314 ref. 
Including only participants with 
persistent thyroid function state ** 
62/905 
0.96  
(0.61-1.51) 
102/1304 
1.04  
(0.68-1.60) 
214/2237 
1.20  
(0.81-1.80) 
78/985 
0.91 
(0.59-1.41) 
27/314 ref. 
Excluding studies           
Excluding studies with AF diagnosis 
without ECG review †† 
282/3912 
1.13 
(0.92-1.39) 
356/3651 
1.05 
(0.86-1.27) 
683/5517 
1.11 
(0.93-1.33) 
334/2673 
1.00 
(0.82-1.21) 
147/1094 ref. 
Excluding studies with >5% lost to 
follow-up ‡‡ 
236/3100 
1.05 
(0.83-1.33) 
324/4515 
1.00 
(0.80-1.25) 
574/7851 
1.03 
(0.83-1.28) 
233/3407 
0.89 
(0.71-1.13) 
99/1354 ref. 
Excluding MrOS Study §§ 364/5595 
1.10 
(0.92-1.32) 
477/6144 
1.03 
(0.87-1.23) 
874/9752 
1.06 
(0.90-1.25) 
402/4254 
0.96 
(0.81-1.14) 
182/1749 ref. 
Excluding SHIP Study |||| 343/4046 
1.10 
(0.92-1.32) 
483/5775 
1.02 
(0.86-1.21) 
891/9820 
1.04 
(0.89-1.22) 
412/4359 
0.94 
(0.79-1.12) 
190/1800 ref. 
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Abbreviations: AF, Atrial Fibrillation; BMI, Body Mass Index; BL, Baseline; CI, Confidence Interval; E, events; ECG, Electrocardiogram; fT4, free Thyroxin; FUP, Follow-up; HR, 
Hazard Ratio; MrOS, Osteoporotic Fractures in Men Study; P, participants; ref., reference; SHIP, Study of Health in Pomerania; TSH, Thyroid Stimulating Hormone 
* Adjusted for age, sex, systolic blood pressure, current and former smoking, diabetes, total cholesterol, and prevalent cardiovascular disease at baseline. 
† For this sensitivity analysis, we added a total of 1177 thyroid medication users (thyroxin or anti-thyroid drugs) to the overall sample: 253 participants in the 
Cardiovascular Health Study; 207 in the Health ABC Study; 43 in the Osteoporotic Fractures in Men Study; 15 in the Bari Study; 12 in the Leiden 85+ Study; 107 in the Study 
of Health in Pomerania; 21 in the Invecchiare in Chianti Study; 26 in the Rotterdam Study; 188 in the PROSPER Study; 301 in the EPIC-Norfolk Study; and, 4 in the Busselton 
Health Study. 
‡ The number of thyroid medication users (thyroxin or anti-thyroid drugs) during follow-up are indicated in Table 1 
§ A total of 123 participants who took amiodarone were excluded for this sensitivity analysis of the association between TSH and AF: 2 participants in the Cardiovascular 
Health Study; 3 in the Health ABC Study; 1 in the Osteoporotic Fractures in Men Study; 79 in the Bari Study; 1 in the Leiden 85+ Study; 1 in the Study of Health in 
Pomerania; 6 in the Invecchiare in Chianti Study; 6 in the Rotterdam Study; 23 in the PROSPER Study; 1 in the EPIC-Norfolk Study. Information on amiodarone use was not 
available in the Busselton Health Study.  
|| A total of 7,786 participants who took other medications that could alter thyroid levels (corticosteroids, amiodarone, iodine, lithium, aspirin, furosemide) were excluded 
for this sensitivity analysis: 1,634 participants in the Cardiovascular Health Study; 881 in the Health ABC Study; 245 in the Osteoporotic Fractures in Men Study; 251 in the 
Bari Study; 56 in the Leiden 85+ Study; 299 in the Study of Health in Pomerania; 122 in the Invecchiare in Chianti Study; 151 in the Rotterdam Study; 3,199 in the PROSPER 
Study; 948 in the EPIC-Norfolk Study.  
#  A total of 311 participants were excluded for this analysis: 22 participants in the Cardiovascular Health Study; 5 in the Leiden 85+ Study; 1 in the InChianti Study; 282 in 
the Rotterdam Study; and 1 in the Busselton Health Study had missing measurements for fT4. In participants in the Health ABC study, fT4 was measured only in participants 
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with TSH 7.0 mIU/L (therefore, no fT4 measurement in 2270 participants) and, in the PROSPER Study, fT4 was measured only in participants with TSH <0.45mIU/l or TSH 
4.5mIU/l (therefore, no fT4 measurement in 4220 participants) 
 ** Persistent thyroid function state was defined as persistent category (euthyroidism, subclinical hypothyroidism) from baseline to follow-up thyroid function test. Follow-
up thyroid function was measured in the Cardiovascular Health Study, Leiden 85-plus Study, PROSPER Study, Study of Health in Pomerania, and the Busselton Health Study. 
†† The Bari and EPIC-Norfolk studies were excluded. 
‡‡ The Cardiovascular Health Study, MrOS Study, SHIP Study, InChianti Study, and Busselton Health Study were excluded. 
§§ In the MrOS Study, thyroid hormones were measured an average of 3.4 years before other baseline characteristics were assessed. 
|| || SHIP includes participants from Pomerania, where an iodine supplementation began in the mid-1990s, which shifted the distribution of TSH values towards the left 
during the first years, and lowered TSH values in the population in the SHIP Study during the baseline examinations in 1997-2001.
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Table 4. Main and Sensitivity Analysis of the Association between Subclinical Hypothyroidism and the Risk of Atrial Fibrillation 
TSH level (mlU/l) 3.50-4.49  4.5-6.9  7.0-9.9  10.0-19.9  
 
Events / 
Participants 
HR 
(95% CI) 
Events / 
Participants 
HR 
(95% CI) 
Events / 
Participants 
HR 
(95% CI) 
Events / 
Participants 
HR 
(95% CI) 
All available cohorts         
Age- and sex-adjusted 190/1806  ref. 149/1384 
0.92 
(0.74-1.14) 
44/383 
1.02 
(0.73-1.41) 
22/191 
0.94 
(0.61-1.47) 
Multivariable adjusted analysis * 187/1777 ref. 149/1365 
0.91 
(0.74-1.14) 
43/377 
0.95 
(0.68-1.33) 
22/189 
0.93 
(0.60-1.44) 
Further adjustments of multivariable models *        
Plus antihypertensive and 
lipid lowering medication 
180/1703 ref. 146/1316 
0.92 
(0.74-1.14) 
41/363 
0.92 
(0.66-1.30) 
22/176 
0.95 
(0.61-1.48) 
Plus BMI 179/1696 ref. 144/1307 
0.92 
(0.74-1.15) 
41/362 
0.93 
(0.66-1.31) 
22/176 
0.96 
(0.61-1.49) 
Medication affecting thyroid function  
     
  
Including all regardless of thyroid 
medication use † 
200/1914 ref. 162/1521 
0.91 
(0.74-1.12) 
47/457 
0.92 
(0.67-1.26) 
33/254 
1.09 
(0.75-1.57) 
Excluding thyroid medication use 
at BL and/or FUP ‡ 
173/1722 ref. 111/1208 
0.89 
(0.70-1.13) 
35/296 
1.27 
(0.88-1.83) 
12/120 
1.07 
(0.60-1.93) 
Excluding users of amiodarone  190/1795 ref. 148/1376 
0.92 
(0.74-1.14) 
44/377 
1.02 
(0.74-1.42) 
20/183 
0.89 
(0.56-1.42) 
Excluding users of other drugs 
affecting thyroid function § 
103/1273 ref. 81/891 
1.08 
(0.81-1.44) 
27/243 
1.29 
(0.84-1.97) 
11/118 
1.15 
(0.62-2.14) 
Thyroid function 
Excluding participants with 
missing values of fT4 || 
147/1314 ref. 124/997 
0.98 
(0.77-1.24) 
40/339 
1.02 
(0.71-1.45) 
22/185 
0.98 
(0.62-1.54) 
Including only participants with 
persistent thyroid function state # 
27/314 ref. 10/159 
0.70 
(0.34-1.44) 
4/84 
0.55 
(0.19-1.57) 
6/43 
1.70 
(0.70-4.12) 
Excluding studies         
Excluding studies with AF 
diagnosis without ECG review ** 
147/1094 ref. 131/951 
0.99 
(0.78-1.25) 
33/245 
0.95 
(0.65-1.39) 
19/132 
1.02 
(0.63-1.65) 
Excluding studies with >5% lost to 
follow-up †† 
99/1354 ref. 60/992 
0.78 
(0.56-1.07) 
22/280 
1.10 
(0.69-1.74) 
8/130 
0.76 
(0.37-1.57) 
Excluding MrOS Study ‡‡ 182/1749 ref. 148/1351 
0.95 
(0.76-1.18) 
43/374 
1.03 
(0.74-1.43) 
22/188 
0.96 
(0.62-1.50) 
Excluding SHIP Study §§ 190/1800 ref. 149/1374 
0.92 
(0.74-1.14) 
44/382 
1.02 
(0.73-1.41) 
22/190 
0.94 
(0.61-1.47) 
38 
 
Abbreviations: AF, Atrial Fibrillation; BMI, Body Mass Index; BL, Baseline; CI, Confidence Interval; ECG, Electrocardiogram; fT4, free Thyroxin;  
FUP, Follow-up; HR, Hazard Ratio; MrOS, Osteoporotic Fractures in Men Study; ref., reference; SHIP, Study of Health in Pomerania; TSH, Thyroid Stimulating Hormone 
* Adjusted for age, sex, systolic blood pressure, current and former smoking, diabetes, total cholesterol, and prevalent cardiovascular disease  
at baseline. 
† Thyroid medication was defined as thyroxin or anti-thyroid drugs. 
‡ The numbers of thyroid medication users during follow-up are indicated in Table 1. 
§ Other medications that could alter thyroid levels: corticosteroids, amiodarone, iodine, lithium, aspirin, furosemide. 
|| A total of 311 participants were excluded for this analysis: fT4 measurements were missing for 22 participants in the Cardiovascular Health Study, 5 in the Leiden 85+ 
Study, 1 in the InChianti Study, 282 in the Rotterdam Study, and 1 in the Busselton Health Study. In participants of the Health ABC study, fT4 was measured only in those 
with TSH  7.0 mIU/L (therefore, no fT4 measurement in 2270 participants); in the PROSPER Study, fT4 was measured only in participants with TSH <0.45mIU/l or TSH 
4.5mIU/l (therefore, no fT4 measurement in 4220 participants). 
# Persistent thyroid function state was defined as persistent category (euthyroidism, subclinical hypothyroidism) from baseline to follow-up thyroid function test. Follow-up 
thyroid function was measured in the Cardiovascular Health Study, Leiden 85-plus Study, PROSPER Study, Study of Health in Pomerania, and the Busselton Health Study. 
** The Bari and EPIC-Norfolk studies were excluded. 
†† The Cardiovascular Health Study, MrOS Study, SHIP Study, InChianti Study, and Busselton Health Study were excluded. 
‡‡ In the MrOS Study, thyroid hormones were measured an average of 3.4 years before atrial fibrillation was first assessed. 
§§ SHIP includes participants from Pomerania, where an iodine supplementation began in the mid-1990s, which shifted the distribution of TSH values towards the left 
during the first years, and lowered TSH values in the population in the SHIP Study during the baseline examinations in 1997-2001.
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Table 5. Main and Sensitivity Analysis of the Association between Quartiles of Free Thyroxine within the Reference Range and the Risk of Atrial Fibrillation * 
fT4 quartile 
First 
quartile 
 
Second 
quartile 
 
Third 
quartile 
 
Fourth 
quartile 
 
 
 
Events / 
Participants 
HR 
(95% CI) 
Events / 
Participants 
HR 
(95% CI) 
Events / 
Participants 
HR 
(95% CI) 
Events / 
Participants 
HR 
(95% CI) 
P for 
trend 
All available cohorts          
Age- and sex-adjusted 371/5642 ref. 390/4989 
1.17 
(1.02-1.35) 
438/5272 
1.25 
(1.09-1.43) 
474/5018 
1.45 
(1.26-1.66) 
0.001 
Multivariable adjusted analysis † 367/5551 ref. 384/4912 
1.16 
(1.00-1.33) 
429/5198 
1.19 
(1.04-1.37) 
472/4947 
1.39 
(1.22-1.60) 
0.001 
Further adjustments of multivariable models †         
Plus antihypertensive and 
lipid lowering medication 
358/4949 ref. 368/4526 
1.12 
(0.97-1.30) 
415/4693 
1.15 
(1.00-1.32) 
450/4494 
1.31 
(1.14-1.50) 
0.001 
Plus BMI 354/4928 ref. 366/4507 
1.13 
(0.98-1.31) 
410/4669 
1.15 
(1.00-1.33) 
447/4469 
1.33 
(1.16-1.53) 
0.001 
Medication affecting thyroid function  
     
   
Including all regardless of thyroid 
medication use ‡ 
380/5731 ref. 429/5194 
1.18 
(1.03-1.36) 
447/5466 
1.29 
(1.12-1.48) 
487/5089 
1.43 
(1.25-1.63) 
0.001 
Excluding thyroid medication use 
at BL and/or FUP § 
355/5533 ref. 390/4969 
1.15 
(1.00-1.33) 
407/5105 
1.25 
(1.08-1.44) 
467/4966 
1.46 
(1.27-1.67) 
0.001 
Excluding users of amiodarone 
|| 
369/5626 ref. 391/4969 
1.18 
(1.03-1.36) 
437/5265 
1.25 
(1.09-1.44) 
468/4998 
1.44 
(1.25-1.65) 
0.001 
Excluding users of other drugs 
affecting thyroid function # 
236/4676 ref. 250/4183 
1.13 
(0.95-1.36) 
288/4359 
1.30 
(1.10-1.55) 
301/4114 
1.44 
(1.21-1.70) 
0.001 
Excluding Studies          
Excluding studies with AF 
diagnosis without ECG review ** 
257/2710 ref. 282/2331 
1.24 
(1.05-1.47) 
293/2545 
1.21 
(1.02-1.43) 
300/2354 
1.39 
(1.18-1.64) 
0.001 
Excluding studies with >5% lost 
to follow-up †† 
174/3517 ref. 181/3202 
1.12 
(0.91-1.37) 
211/3306 
1.27 
(1.04-1.55) 
237/3202 
1.44 
(1.18-1.75) 
0.001 
Excluding MrOS Study ‡‡ 361/5475 ref. 373/4837 
1.15 
(1.00-1.33) 
424/5126 
1.24 
(1.07-1.42) 
457/4864 
1.43 
(1.24-1.64) 
0.001 
Aggregate data          
Including aggregate data of the 
Rotterdam Study Cohorts I, II, 
and III §§ 
402/7186 ref. 428/6545 
1.15 
(1.01-1.32) 
473/6812 
1.22 
(1.07-1.39) 
533/6545 
1.45  
(1.27-1.65) 
0.017 
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Abbreviations: AF, Atrial Fibrillation; BMI, Body Mass Index; BL, Baseline; CHS, Cardiovascular Health Study; CI, Confidence Interval; ECG, Electrocardiogram; fT4, free 
Thyroxin; FUP, Follow-up; HR, Hazard Ratio; MrOS, Osteoporotic Fractures in Men Study; ref., reference; SHIP, Study of Health in Pomerania; TSH, Thyroid Stimulating 
Hormone. 
* This analysis was restricted to normal thyroid function (TSH and free thyroxine in the reference range). From the overall sample, we excluded 9164 participants for this 
analysis because their fT4 measurements were missing or their thyroid function was outside the reference range: 479 participants in the Cardiovascular Health Study; 59 in 
the Osteoporotic Fractures in Men Study; 32 in the Bari Study; 137 in the Leiden 85+ Study; 125 in the Study of Health in Pomerania; 42 in the InChianti Study; 365 in the 
Rotterdam Study; 897 in the EPIC-Norfolk Study; and, 57 in the Busselton Health Study. In participants of the Health ABC Study, fT4 was measured only in TSH  7.0 mIU/L, 
so we excluded all 2346 participants for this analysis. In the PROSPER Study, fT4 was measured only in participants with TSH <0.45mIU/l or TSH 4.5mIU/l, so, 4625 
participants were excluded from this analysis. The first quartile was the lowest one. 
† Adjusted for age, sex, systolic blood pressure, current and former smoking, diabetes, total cholesterol, and prevalent cardiovascular disease at baseline. 
‡ A total of 559 participants with thyroid medication use (thyroxin or anti-thyroid drugs) at baseline were additionally added for this analysis: 167 participants in the CHS; 
33 of the MrOS; 9 in the Bari Study; 5 in the Leiden 85+ Study; 85 in the SHIP; 16 in the InChianti Study; 9 in the Rotterdam Study; 8 in the PROSPER Study; 224 in the EPIC-
Norfolk Study; and 3 in the Busselton Health Study. 
§ A total of 348 participants were on thyroid medication during follow-up: 139 participants in the CHS; 11 in the MrOS; 15 in the Bari Study; 3 in the Leiden 85+ Study; 156 
in the SHIP; 13 in the InChianti Study; 2 in the PROSPER Study; and 9 in the Busselton Health Study.  
|| A total of 63 participants who took amiodarone were excluded for this sensitivity analysis of the association between fT4 and AF: 1 participant in the CHS; 1 in the MrOS; 
57 in the Bari Study; 3 in the InChianti Study; and 1 in the EPIC-Norfolk Study. Information on amiodarone use was not available in the Busselton Health Study. 
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# We excluded a total of 3,589 participants with intake of other medications that could alter thyroid levels (corticosteroids, amiodarone, iodine, lithium, aspirin, 
furosemide) for this analysis: 1,395 participants in the CHS; 215 in the MrOS Study; 220 in the Bari Study; 33 in the Leiden 85+ Study; 286 in the SHIP; 111 in the InChianti 
Study; 103 in the Rotterdam Study; 348 in the PROSPER Study; and 878 in the EPIC-Norfolk Study. 
** The Bari and EPIC-Norfolk studies were excluded. We excluded a total of 10,981 participants from this sensitivity analysis: 236 participants in the Bari Study, and 10,745 
in the EPIC-Norfolk Study. 
†† The Cardiovascular Health Study, MrOS Study, SHIP Study, InChianti Study, and Busselton Health Study were excluded. 
‡‡ In the MrOS Study, thyroid hormones were measured an average of 3.4 years before the first assessment of atrial fibrillation. 
§§ Individual participant data were not available from the study by Chaker et al., which included aggregate results from the Rotterdam Study Cohorts I, II, and III.24 For this 
sensitivity analysis, we excluded individual participant data from the Rotterdam Study Cohort I (1244 participants with 171 events) that we had obtained from an earlier 
publication16 in order to avoid duplicate participants 
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Supplemental	Methods	1.	Data	Sources	and	Search	Strategies	
We	performed	a	systematic	literature	review	on	the	risk	of	atrial	fibrillation	across	the	full	TSH	range	in	
MEDLINE	and	EMBASE	databases	without	language	restriction	from	inception	to	July	27,	2016.	We	did	our	
search	on	an	Ovid	(MEDLINE)	server	by	using	broadly	defined	Medical	Subject	Headings	(MeSH):	thyroid	
diseases,	hypothyroidism,	hyperthyroidism,	thyroid	hormones,	thyrotropin,	atrial	fibrillation,	arrhythmia;	and	
the	following	keywords:	subclinical	hypothyroidism,	subclinical	hyperthyroidism,	subclinical	dysthyroidism,	
subclinical	thyroid,	and	euthyroid.	We	used	the	filter	designed	by	knowledge	information	specialists	from	BMJ	
to	select	prospective	studies	(MEDLINE	cohort-study	filter)1	but	without	their	year	limitation.	A	search	in	
EMBASE	was	done	using	similar	terms.	We	also	conducted	a	manual	literature	search	with	review	of	expert	
papers	in	the	field	and	screened	bibliographies	from	retrieved	articles.		
	 	
Supplemental	Methods	2.	Study	Quality	Assessment	
Following	individual	criteria	of	the	Newcastle-Ottawa	Quality	Assessment	Scale2	were	assessed:	1-2)	
representativeness	of	the	exposed/unexposed	cohort	(populations-based	vs.	convenience	based),	3)	
ascertainment	of	exposure	(thyroid	function	measurement),	4)	demonstration	that	outcome	of	interest	(atrial	
fibrillation)	was	not	present	at	start	of	study,	5)	availability	of	relevant	confounders	for	adjustment,	6)	objective	
assessment	of	outcome	(assessment	of	atrial	fibrillation	by	electrocardiogram),	7)	adequate	length	of	follow-up	
period	(>5	years),	and	8)	loss	of	follow-up	(<5%).	Two	authors	independently	assessed	study	quality	(C.B.	and	
C.F.).	
	 	
Supplemental	Table	1.	Definition	of	Baseline	Covariates	
Study	 Smoking	 Diabetes	 Prevalent	Cardiovascular	Disease		
Cardiovascular	Health	
Study4	
Self-reported	never,	former,	or	
current	smoking	(³100	
cigarettes	in	entire	life)	
Fasting	glucose	level	of	³126mg/dL	or	use	of	
hypoglycemic	medication	
History	of	myocardial	infarction	or	angina	or	CABG	or	angioplasty	
or	stroke	or	TIA	(adjudicated)	
Health	ABC	Study9	 Self-reported	never,	former,	or	
current	smoking	(³100	
cigarettes	in	entire	life)	
Self-reported	diagnosis	of	diabetes	or	use	of	
hypoglycemic	medication	
Self-reported	history	of	myocardial	infarction	or	angina	with	use	
of	antianginal	medications	or	CABG	or	angioplasty	or	stroke	or	
TIA		
Osteoporotic	Fractures	
in	Men	(MrOS)	Study10	
Self-reported	never,	former,	or	
current	smoking	
Self-reported	diagnosis	of	diabetes	 Self-reported	myocardial	infarction	or	stroke		
Bari	Study11	 Self-reported	non-smoker	or	
current	smoker	(regular	
smoking	within	last	30	days)	
Physician	diagnosis	of	diabetes	 History	of	myocardial	infarction	or	angina	or	CABG	or	angioplasty	
or	stroke	(assessed	by	review	of	medical	records)	
Leiden	85-plus	Study12	 Self-reported	never,	former,	or	
current	smoking	
Physician	diagnosis	of	diabetes	or	use	of	
hypoglycemic	medication	
History	of	myocardial	infarction	or	angina	or	stroke	(assessed	by	
review	of	medical	records,	physician	or	self-report,	and	ECG)	
SHIP13	 Self-reported	never,	former,	or	
current	smoking	
Self-reported	or	physician	diagnosis	of	
diabetes	
Self-reported	myocardial	infarction	or	CABG	or	stroke		
InChianti	Study14	 Self-reported	never,	former,	or	
current	smoking	(if	at	least	1	
year	of	cigarette	smoking)	
Fasting	blood	glucose	>140	mg/dL	or	
glucosuria	
History	of	myocardial	infarction	or	angina	or	perfusion	
deficit/asynergy	in	scintigraphy	or	severe	stenosis	in	coronary	
angiography	or	CABG	or	angioplasty	or	stroke	(adjudicated)	
Rotterdam	Study8	 Self-reported	never,	former,	or	
current	smoking	
Random	or	post-load	serum	glucose	level	of	
200mg/dL	or	higher,	or	use	of	hypoglycemic	
medication	
History	of	myocardial	infarction	or	revascularization	or	stroke	
(assessed	by	self-report,	ECG,	review	of	nationwide	Medical	
Registry,	screening	of	physician	records)	
PROSPER	Study15	 Self-reported	never,	current,	or	
former	smoking	
Self-reported	diagnosis	of	diabetes	or	use	of	
hypoglycemic	drugs	or	fasting	blood	glucose	
of	7.0mmol/l	or	11.1mmol/l	or	greater	when	
fasting	status	was	uncertain	
Physician	diagnosis	of	vascular	disease	or	myocardial	infarction	
or	angina	or	CABG	or	angioplasty	or	stroke	or	TIA		
EPIC-Norfolk	Study16	 Self-reported	never,	former,	or	
current	smoking	(if	³1	cigarette	
a	day	for	³1	year)	
Self-reported	diagnosis	of	diabetes	 Self-reported	myocardial	infarction	or	stroke		
Busselton	Health	Study17	 Self-reported	never,	former,	or	
current	smoking	
Self-reported	diagnosis	of	diabetes,	use	of	
hypoglycemic	drugs,	or	glucose	level	>200	
mg/dL	2	hours	after	glucose	load	
History	of	myocardial	infarction	or	angina	(assessed	by	self-
reported	confirmation	of	physician	diagnosis,	Rose	
questionnaire,	ECG)	
	Abbreviations:	CABG,	coronary	artery	bypass	surgery;	ECG,	electrocardiogram;	TIA,	transient	ischemic	attack	
	Supplemental	Table	2.	Studies	Excluded	after	Full	Text	Screening	
Reason	for	exclusion	 References	
Review,	meeting	abstract,	poster	or	
editorial	
Erichsen	R,	Christiansen	CF,	Froslev	T,	Jacobsen	J,	Sorensen	HT.	Intravenous	bisphosphonate	therapy	and	risk	of	atrial	fibrillation	in	
cancer	patients.	Pharmacoepidemiology	and	Drug	Safety.	2011;20((Erichsen	R.;	Christiansen	C.F.;	Froslev	T.;	Jacobsen	J.;	
Sorensen	H.T.)	Department	of	Clinical	Epidemiology,	Aarhus	University	Hospital,	Aarhus	N,	Denmark):S121.	
Kim	SC,	Liu	J,	Solomon	DH.	The	risk	of	atrial	fibrillation	in	patients	with	rheumatoid	arthritis	compared	to	the	general	population:	A	
large	cohort	study.	Arthritis	and	Rheumatism.	2012;64((Kim	S.C.)	Brigham	and	Women's	Hospital,	Boston,	United	
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Supplemental	Table	3.	Baseline	Characteristics	of	Participants	by	Thyroid	Function	
Characteristic	
Euthyroidism	
(n=28,127)	
Subclinical	Hypothyroidism	
(n=1,958)	 p-value*	
Age	in	y,	mean	(SD)	 64.4	(13.5)	 69.9	(10.0)	 <0.001	
Women,	n	(%)	 14,285	(50.8)	 1,223	(62.5)	 <0.001	
Caucasian,	n	(%)	†	 18,095	(91.8)	 1,406	(91.8)	 0.92	
Body	mass	index	in	kg/m2,	mean	(SD)	‡	 26.6	(4.2)	 26.8	(4.3)	 0.072	
Thyroid	stimulating	hormone	in	mIU/L,	mean	(SD)	 1.81	(0.91)	 6.68	(2.59)	 <0.001	
Present	or	former	smoker,	n	(%)	 15,799	(56.2)	 980	(50.1)	 <0.001	
Systolic	blood	pressure	in	mmHg,	mean	(SD)	§	 139.2	(21.5)	 139.6	(22.4)	 0.36	
Total	cholesterol	in	mmol/l,	mean	(SD)	||		 6.08	(1.67)	 5.94	(1.38)	 <0.001	
Cardiovascular	disease,	n	(%)	 4,928	(17.5)	 443	(22.6)	 <0.001	
Heart	failure,	n	(%)	 655	(2.3)	 59	(3.0)	 0.054	
Stroke,	n	(%)	 624	(2.2)	 61	(3.1)	 0.010	
Diabetes,	n	(%)	 2,108	(7.5)	 196	(10.0)	 <0.001	
Antihypertensive	medication,	n	(%)	 10,593	(37.7)	 878	(44.8)	 <0.001	
Lipid-lowering	medication,	n	(%)	 3,772	(13.4)	 305	(15.6)	 0.007	
Amiodarone,	n	(%)	#	 101	(0.4)	 22	(1.1)	 <0.001	
Abbreviation:	SD,	standard	deviation.		
*p-values	were	derived	from	a	chi-squared	test	or	Student’s	t-test,	as	appropriate	
†	Information	on	race	was	missing	in	8,408	(29.9%)	participants	with	euthyroidism	and	427	(21.8%)	with	
subclinical	hypothyroidism	
‡	Information	on	body	mass	index	was	missing	in	128	(0.5%)	participants	with	euthyroidism	and	11	(0.6%)	with	
subclinical	hypothyroidism	
§	Information	on	systolic	blood	pressure	was	missing	in	79	participants	with	euthyroidism	(0.3%)	and	4	(0.2%)	
with	subclinical	hypothyroidism	
||	Information	on	total	cholesterol	was	missing	in	126	(0.4%)	participants	with	euthyroidism	and	7	(0.4%)	with	
subclinical	hypothyroidism	
#	Information	on	amiodarone	use	at	baseline	was	missing	in	all	participants	of	the	Busselton	Health	Study	
(1,023	participants	with	euthyroidism	and	37	with	subclinical	hypothyroidism)	
	Supplemental	Table	4.	Quality	Assessment	of	Included	Studies*	
Study		 Population	
studied	†	
Ascertainment	
of	exposure	‡		
Assessment	
of	AF	at	
baseline	
Controlling	for	additional	factors		 Methods	for	AF	ascertainment	 Duration	of	
follow-up,	
median	(IQR),	y	
Lost	to	
follow-
up	(%)		
United	States	 	 	 	 	 	 	 	
Cardiovascular	
Health	Study		
P,	4	
communities	
(USA)	
Third	
generation	TSH	
assay	
yes	 age	and	sex,	systolic	blood	pressure,	
current	or	former	smoking,	diabetes	
mellitus,	total	cholesterol,	and	prevalent	
cardiovascular	disease,	lipid	lowering	
medications,	antihypertensive	
medications,	BMI,	heart	rate,	and	
alcohol	consumption	
Self-report,	annual	ECG,	ICD-9	
hospital	discharge	codes	
	
11.7	(7.0-18.1)	 7.9-
10.1	
Health	ABC	
Study	
P,	2	cities	
(USA)	
Third	
generation	TSH	
assay	
yes	 age	and	sex,	systolic	blood	pressure,	
current	or	former	smoking,	diabetes	
mellitus,	total	cholesterol,	and	prevalent	
cardiovascular	disease,	lipid	lowering	
medications,	antihypertensive	
medications,	BMI,	heart	rate,	and	
alcohol	consumption	
Recoded	Minnesota	at	baseline	
and	year	4	follow-up	visits,	ICD-9	
coded	diagnoses	from	CMS	
(center	for	Medicare	and	
Medicaid)	data	
8.1	(7.4-8.3)	 <5	
Osteoporotic	
Fractures	in	
Men	(MrOS)	
Study	
P,	6	clinical	
centers	(USA)	
Third	
generation	TSH	
assay	
yes	 age	and	sex,	systolic	blood	pressure,	
current	or	former	smoking,	diabetes	
mellitus,	total	cholesterol,	and	prevalent	
cardiovascular	disease,	lipid	lowering	
medications,	antihypertensive	
medications,	BMI,	heart	rate,	and	
alcohol	consumption	
self	report	and	ECG	at	baseline,	
medical	records	and	supporting	
documentation	collected	every	
4months	(phone	or	postcard	
follow-up)	
12.6	(11.2-13.1)	 6		
Europe	 	 	 	 	 	 	 	
Bari	Study	 Outpatients	
with	
congestive	
heart	failure	
(Italy)	
Third	
generation	TSH	
assay	
yes	 age	and	sex,	systolic	blood	pressure,	
current	or	former	smoking,	diabetes	
mellitus,	total	cholesterol,	and	prevalent	
cardiovascular	disease,	lipid	lowering	
medications,	antihypertensive	
medications,	BMI		
ICD-9	at	discharge	 1.3	(0.6-1.9)	 <5	
Leiden	85+	
Study	
P,	1	town	
(Leiden,	The	
Netherlands)	
Third	
generation	TSH	
assay	
yes	 age	and	sex,	systolic	blood	pressure,	
current	or	former	smoking,	diabetes	
mellitus,	total	cholesterol,	and	prevalent	
cardiovascular	disease,	lipid	lowering	
medications,	antihypertensive	
medications,	BMI,	and	alcohol	
consumption	
Annual	ECG,	Minnesota	 5.5	(2.7-9.0)	 <5	
Study	of	
Health	in	
Pomerania	
P,	1	region	
(West	
Pomerania,	
Germany)	
Third	
generation	TSH	
assay	
yes	 age	and	sex,	systolic	blood	pressure,	
current	or	former	smoking,	diabetes	
mellitus,	total	cholesterol,	and	prevalent	
cardiovascular	disease,	lipid	lowering	
medications,	antihypertensive	
medications,	BMI,	heart	rate	
Minnesota	at	baseline	+	year	5	
follow-up	and	ongoing	year	10	
follow-up	
11.5	(11.1-12.1)	 37	
Invecchiare	in	
Chianti	Study	
P,	2	towns	in	
Toscany	(Italy)	
Third	
generation	TSH	
assay	
yes	 age	and	sex,	systolic	blood	pressure,	
current	or	former	smoking,	diabetes	
mellitus,	total	cholesterol,	and	prevalent	
cardiovascular	disease,	lipid	lowering	
medications,	antihypertensive	
medications,	BMI,	heart	rate,	and	
alcohol	consumption	
ECG	at	baseline	and	year	3	
follow-up,	year	6	follow-up	and	
year	9	follow-up	
9.0	(8.3-9.2)	 35	
Rotterdam	
Study	
P,	1	district	
(The	
Netherlands)	
Third	
generation	TSH	
assay	
yes	 age	and	sex,	systolic	blood	pressure,	
current	or	former	smoking,	diabetes	
mellitus,	total	cholesterol,	and	prevalent	
cardiovascular	disease,	lipid	lowering	
medications,	antihypertensive	
medications,	BMI,	heart	rate,	and	
alcohol	consumption	
i)	12	lead	ECG	at	baseline	and	
follow-up	visits	ii)	ICD-10	coded	
info	from	GPs	(own	records,	
hospital	discharge	letters)	with	
requirement	of	ECG	verifying	the	
diagnosis	iii)	hospital	discharge	
diagnoses	through	Dutch	
National	Medical	Registration	
15.5	(11.4-16.9)	 0.9	
PROSPER	
Study	
Primary	care	
patients,	in	3	
countries	(The	
Netherlands,	
Ireland,	
Scotland)	
Third	
generation	TSH	
assay	
yes	 age	and	sex,	systolic	blood	pressure,	
current	or	former	smoking,	diabetes	
mellitus,	total	cholesterol,	and	prevalent	
cardiovascular	disease,	lipid	lowering	
medications,	antihypertensive	
medications,	BMI,	heart	rate,	and	
alcohol	consumption	
Annual	single-lead	ECG	or	12-lead	
ECG	or	telemetry	during	
hospitalization	or	other	clinical	
care	
3.3	(3.0-3.5)	 <5	
EPIC-Norfolk	 P,	1	county	
(Norfolk,	
England)	
Third	
generation	TSH	
assay	
yes	 age	and	sex,	systolic	blood	pressure,	
current	or	former	smoking,	diabetes	
mellitus,	total	cholesterol,	and	prevalent	
cardiovascular	disease,	lipid	lowering	
medications,	antihypertensive	
medications,	BMI,	heart	rate,	and	
alcohol	consumption	
Baseline:	self-reported	intake	of	
drugs	used	for	AF	treatment:	
digitalis	and	vitamin	K	
antagonists.	Incident	AF:	ICD-10	
coded	hospital	discharge	codes		
17.0	(16.1-18.0)	 <2	
Australia	 	 	 	 	 	 	 	
Busselton	
Health	Study	
P,	1	district	
(Busselton,	
Australia)	
Third	
generation	TSH	
assay	
yes	 age	and	sex,	systolic	blood	pressure,	
current	or	former	smoking,	diabetes	
mellitus,	total	cholesterol,	and	prevalent	
cardiovascular	disease,	antihypertensive	
medications,	BMI	
ECG	at	baseline	and	year	14	
follow-up	
14.0	(14.0-14.0)	 37	
	
Abbreviations:	AF,	atrial	fibrillation;	BMI,	body	mass	index;	ECG,	electrocardiogram;	GP,	general	practitioner;	NR,	not	reported;	P,	population-based	study.		
*If	an	article	did	not	clearly	mention	one	of	these	characteristics,	we	considered	that	is	had	not	been	done.	All	included	studies	were	prospective	cohort	studies.	
†	A	population-based	study	was	defined	as	a	random	sample	of	the	general	population.		
‡	A	formal	adjudication	procedure	was	defined	as	having	clear	criteria	for	the	outcome	that	were	reviewed	by	experts	for	each	potential	case.	
	
	
	
	
	
	
	
	
Supplemental	Table	5.	Sensitivity	Analyses	of	the	Association	between	Thyroid	Stimulating	Hormone	within	the	Reference	Range	and	the	Risk	of	Atrial	Fibrillation	
TSH	level	(mlU/l)	 0.45-0.99	 	 1.00-1.49	 	 1.50-2.49	 	 2.50-3.49	 	 3.50-4.49	 	
	 Events	/	Persons	
HR	
(95%	CI)	
Events	/	
Persons	
HR	
(95%	CI)	
Events	/	
Persons	
HR	
(95%	CI)	
Events	/	
Persons	
HR	
(95%	CI)	
Events	/	
Persons	
HR	
(95%	CI)	
Main	analysis		
(age-	and	sex-adjusted)	 372/5665	
1.10	
(0.92-1.31)	 492/6275	
1.03	
(0.87-1.22)	 893/9990	
1.04	
(0.89-1.22)	 412/4391	
0.94	
(0.79-1.12)	 190/1806	 ref.	
Excluding	users	of	amiodarone	and	
a	study	with	missing	relevant	data*		 365/5369	
1.09	
(0.91-1.30)	 485/5956	
1.02	
(0.86-1.21)	 883/9622	
1.03	
(0.88-1.21)	 408/4293	
0.93	
(0.78-1.11)	 190/1763	 ref.	
Excluding	thyroid	medication	use		
at	BL	and/or	FUP	and	studies	with	
missing	relevant	data	†	
225/3510	 1.05	(0.84-1.32)	 306/3286	
1.01	
(0.82-1.25)	 596/4994	
1.06	
(0.88-1.29)	 292/2412	
0.96	
(0.78-1.18)	 124/945	 ref.	
Abbreviations:	BL,	baseline;	CI,	confidence	interval;	FUP,	follow-up;	HR,	hazard	ratio;	TSH,	thyroid	stimulating	hormone.	
*	A	total	of	1,183	participants	were	excluded	for	this	sensitivity	analysis	of	the	association	between	TSH	and	atrial	fibrillation:	2	participants	who	took	amiodarone	in	the	
Cardiovascular	Health	Study;	3	in	the	Health	ABC	Study;	1	in	the	Osteoporotic	Fractures	in	Men	Study;	79	in	the	Bari	Study;	1	in	the	Leiden	85+	Study;	1	in	the	Study	of	Health	in	
Pomerania;	6	in	the	Invecchiare	in	Chianti	Study;	6	in	the	Rotterdam	Study;	23	in	the	PROSPER	Study;	1	in	the	EPIC-Norfolk	Study,	and	all	1,060	participants	from	the	Busselton	
Health	Study,	in	which	information	on	amiodarone	use	was	not	available.	
†	The	number	of	thyroid	medication	users	during	follow-up	are	indicated	in	Table	1.	We	additionally	excluded	11,642	participants	in	the	EPIC-Norfolk	Study	and	1,607	in	the	
Rotterdam	Study	from	this	sensitivity	analysis	on	the	association	between	TSH	and	atrial	fibrillation,	because	information	on	thyroid	medication	use	during	follow-up	was	not	
available	in	these	studies.		
	
	 	
Supplemental	Table	6.	Stratified	Analyses	for	the	Association	between	Thyroid	Stimulating	Hormone	within	the	Reference	Range	and	Atrial	Fibrillation*	
TSH	level	(mlU/l)	 0.45-0.99	 	 	 1.00-1.49	 	 	 1.50-2.49	 	 	 2.50-3.49	 	 	 3.50-4.49	
Variable	 Events/		Persons	
HR	
(95%	CI)	
HR	
(95%CI)	
Events/		
Persons	
HR	
(95%	CI)	
HR	
(95%	CI)	
Events/		
Persons	
HR	
(95%	CI)	
HR	
(95%	CI)	
Events/		
Persons	
HR	
(95%	CI)	
HR	
(95%	CI)	
Events/		
Persons	
	 	 Age/Sex	Adj	 Multivariate	Model	§	
	 Age/Sex	Adj	 Multivariate	Model	‡	
	 Age/Sex	Adj	 Multivariate	Model	‡	
	 Age/Sex	Adj	 Multivariate	Model	‡	
	
Total	
Population	 372/5665	
1.10		
(0.92-1.31)	
1.07	
(0.89-1.28)	 492/6275	
1.03	
(0.87-1.22)	
0.99	
(0.84-1.18)	 893/9990	
1.04	
(0.89-1.22)	
1.02	
(0.87-1.19)	 412/4391	
0.94	
(0.79-1.12)	
0.92	
(0.78-1.10)	 190/1806	
Age,	y	 	 	 	 	 	 	 	 	 	 	 	 	 	
18-64	 59/3051	 0.82	(0.48-1.42)	
0.86	
(0.50-1.47)	 67/2760	
0.83	
(0.49-1.41)	
0.87	
(0.51-1.47)	 102/3935	
0.81	
(0.49-1.33)	
0.78	
(0.47-1.30)	 34/1367	
0.81	
(0.46-1.44)	
0.78	
(0.44-1.37)	 18/563	
≥65	 313/2614	 1.06	(0.88-1.28)	
1.04	
(0.86-1.25)	 425/3515	
0.97	
(0.82-1.16)	
0.94	
(0.79-1.13)	 791/6055	
1.03	
(0.87-1.21)	
1.01	
(0.85-1.19)	 378/3024	
0.92	
(0.77-1.11)	
0.91	
(0.76-1.09)	 172/1243	
P	for	Trend	 	 0.97	 0.97	 	 0.97	 0.97	 	 0.97	 0.97	 	 0.97	 0.97	 	
Sex	 	 	 	 	 	 	 	 	 	 	 	 	 	
Women	 160/2791	 1.03		(0.80-1.32)	
1.00		
(0.78	-1.28)	 210/3079	
0.97		
(0.76-1.22)	
0.93	
	(0.74-1.18)	 408/4967	
1.02		
(0.82-1.26)	
1.00	
(0.80-	1.24)	 202/2352	
0.93		
(0.74-1.18)	
0.91	
	(0.72-1.16)	 107/1096	
Men	 212/2874	 1.16		(0.89-1.50)	
1.13		
(0.87-1.47)	 282/3196	
1.11		
(0.87-1.42)	
1.07		
(0.83-1.37)	 485/5023	
1.09		
(0.86	to	1.38)	
1.06		
(0.84-1.35)	 210/2039	
0.97		
(0.75-1.25)	
0.95	
	(0.73-1.23)	 83/710	
P	for	Interaction	 	 0.64	 0.81	 	 0.64	 0.81	 	 0.64	 0.81	 	 0.64	 0.81	 	
Race	†	 	 	 	 	 	 	 	 	 	 	 	 	 	
White	 247/2763	 1.19	(0.97-1.46)	
1.17	
(0.95-1.44)	 332/4059	
1.00	
(0.83-1.22)	
0.96	
(0.79-1.17)	 619/6922	
1.01	
(0.84-1.20)	
0.97	
(0.81-1.17)	 292/3038	
0.90	
(0.74-1.09)	
0.87	
(0.72-1.06)	 153/1313	
Non-white	 23/268	 0.95	(0.42-2.12)	
0.92	
(0.41-2.07)	 47/381	
1.48	
(0.70-3.13)	
1.38	
(0.65-2.93)	 68/610	
1.40	
(0.67-2.91)	
1.34		
(0.64-2.80)	 35/264	
1.63	
(0.75-3.51)	
1.51	
(0.70-3.27)	 8/101	
P	for	Interaction	 	 0.037	 0.033	 	 0.037	 0.033	 	 0.037	 0.033	 	 0.037	 0.033	 	
Previous	CVD	 	 	 	 	 	 	 	 	 	 	 	 	 	
None	‡	 263/4876	 1.15	(0.93-1.42)	
1.14	
(0.92-1.41)	 349/5196	
1.10	
(0.90-1.34)	
1.08	
(0.88-1.32)	 616/8186	
1.07	
(0.89-1.29)	
1.05	
(0.87-1.28)	 278/3471	
0.96	
(0.78-1.18)	
0.96	
(0.78-1.19)	 132/1470	
Yes	 109/789	 0.91	(0.66-1.26)	
0.91	
(0.66-1.26)	 143/1079	
0.82	
(0.61-1.12)	
0.81	
(0.60-1.10)	 277/1804	
0.92	
(0.70-1.23)	
0.93	
(0.70-1.24)	 134/920	
0.84	
(0.62-1.14)	
0.83	
(0.60-1.13)	 58/336	
P	for	Interaction	 	 0.78	 0.74	 	 0.78	 0.74	 	 0.78	 0.74	 	 0.78	 0.74	 	
Thyroxine	use	at	
BL	
	 	 	 	 	 	 	 	 	 	 	 	 	
None	 372/5665	 1.10	(0.92-1.31)	
1.07	
(0.89-1.28)	 492/6275	
1.03	
(0.87-1.22)	
0.99	
(0.84-1.18)	 893/9990	
1.04	
(0.89-1.22)	
1.02	
(0.87-1.19)	 412/4391	
0.94	
(0.79-1.12)	
0.92	
(0.78-1.10)	 190/1806	
Yes	 27/244	 1.28	(0.62-2.66)	
1.45	
(0.68-3.10)	 22/154	
1.57	
(0.74-3.33)	
1.65	
(0.76-3.60)	 32/233	
1.52	
(0.74-3.10)	
1.60	
(0.76-3.37)	 19/139	
1.42	
(0.66-3.07)	
1.52	
(0.68-3.39)	 10/105	
P	for	Interaction	 	 0.37	 0.31	 	 0.37	 0.31	 	 0.37	 0.31	 	 0.37	 0.31	 	
Abbreviations:	Adj,	adjusted;	AF,	atrial	fibrillation;	BL,	baseline;	CI,	confidence	interval;	CVD,	cardiovascular	disease;	E,	events;	HR,	hazard	ratio;	NA,	data	not	applicable;	P,	
participants;	TSH,	thyroid-stimulating	hormone	
*	The	TSH	category	3.50-4.49mIU/l	was	the	reference	category	
†	African	Americans,	Hispanics,	Asian,	and	others	were	considered	as	non-white	population.	Data	on	race	were	missing	for	all	participants	of	the	SHIP	study,	the	InChianti	
Study,	and	the	PROSPER	Study,	67	participants	of	the	Rotterdam	Study	and	44	of	the	EPIC-Norfolk	Study.	
‡	Previous	cardiovascular	was	defined	as	a	history	of	stroke,	transient	ischemic	attack,	myocardial	infarction,	angina	pectoris,	coronary	angioplasty,	bypass	surgery.	Participants	
without	any	of	these	events	were	considered	having	no	previous	cardiovascular	disease.	
§	Adjusted	for	age,	sex,	systolic	blood	pressure,	current	and	former	smoking,	diabetes,	total	cholesterol	and	prevalent	cardiovascular	disease.	
	
	 	
Supplemental	Table	7.	Sensitivity	Analyses	of	the	Association	between	Subclinical	Hypothyroidism	and	the	Risk	of	Atrial	Fibrillation	
TSH	level	(mlU/l)	 3.50-4.49	 	 4.5-6.9	 	 7.0-9.9	 	 10.0-19.9	 	
	 Events	/	Participants	
HR	
(95%	CI)	
Events	/	
Participants	
HR	
(95%	CI)	
Events	/	
Participants	
HR	
(95%	CI)	
Events	/	
Participants	
HR	
(95%	CI)	
Main	analysis		
(age-	and	sex-adjusted)	 190/1806		 ref.	 149/1384	
0.92	
(0.74-1.14)	 44/383	
1.02	
(0.73-1.41)	 22/191	
0.94	
(0.61-1.47)	
Excluding	users	of	amiodarone	and	a	
study	with	missing	relevant	data*		 190/1763	 ref.	 146/1355	
0.90	
(0.73-1.12)	 43/371	
1.00	
(0.72-1.39)	 20/173	
0.90	
(0.57-1.42)	
Excluding	thyroid	medication	use		
at	BL	and/or	FUP	and	studies	with	
missing	relevant	data	†	
124/945	 ref.	 81/719	 0.87	(0.66-1.16)	 22/147	
1.22	
(0.78-1.92)	 11/60	
1.56	
(0.84-2.90)	
Abbreviations:	BL,	baseline;	CI,	confidence	interval;	FUP,	follow-up;	HR,	hazard	ratio;	TSH,	thyroid	stimulating	hormone.	
*	Information	on	amiodarone	use	at	baseline	was	not	available	in	the	Busselton	Health	Study.	
†	The	number	of	thyroid	medication	users	during	follow-up	are	indicated	in	Table	1.	We	additionally	excluded	participants	in	the	EPIC-Norfolk	Study	and	the	Rotterdam	Study,	
because	information	on	thyroid	medication	use	during	follow-up	was	not	available	in	these	studies.		
	
	 	
Supplemental	Table	8.	Stratified	Analyses	for	the	Association	between	Subclinical	Hypothyroidism	and	Atrial	Fibrillation*	
TSH	level	(mlU/l)	 3.50-4.49	 4.5-6.9	 	 	 7.0-9.9	 	 	 10.0-19.9	 	 	
Variable	 Events/		Persons	
Events/		
Persons	
HR	
(95%	CI)	
HR	
(95%CI)	
Events/		
Persons	
HR	
(95%	CI)	
HR	
(95%	CI)	
Events/		
Persons	
HR	
(95%	CI)	
HR	
(95%	CI)	
	 	 	 Age/Sex	Adj	 Multivariate	Model	§	
	 Age/Sex	Adj	 Multivariate	Model	‡	
	 Age/Sex	Adj	 Multivariate	Model	‡	
Total	
Population	 190/1806	 149/1384	
0.92	
(0.74-1.14)	
0.91	
(0.74-1.14)	 44/383	
1.02	
(0.73-1.41)	
0.95	
(0.68-1.33)	 22/191	
0.94	
(0.61-1.47)	
0.93	
(0.60-1.44)	
Age	 	 	 	 	 	 	 	 	 	 	
18-64	 18/563	 7/339	 0.69	(0.29-1.64)	
0.67	
(0.28-1.60)	 2/91	
0.72	
(0.17-3.09)	
0.79	
(0.18-3.40)	 1/51	
0.66	
(0.09-4.95)	
0.76	
(0.10-5.70)	
≥65	 172/1243	 142/1045	 0.95	(0.76-1.19)	
0.96		
(0.76-1.19)	 42/292	
1.02	
(0.72-1.42)	
0.96	
(0.68-1.34)	 21/140	
1.05	
(0.67-1.65)	
1.03	
(0.65-1.62)	
P	for	Trend	 	 	 0.97	 0.97	 	 0.97	 0.97	 	 0.97	 0.97	
Sex	 	 	 	 	 	 	 	 	 	 	
Women	 107/1096	 75/853	 0.79	(0.59-1.06)	
0.80	
(0.60-1.08)	 25/249	
0.96	
(0.62-1.48)	
0.90	
(0.58-1.40)	 10/121	
0.71	
(0.37-1.37)	
0.73	
(0.38-1.39)	
Men	 83/710	 74/531	 1.11	(0.81-1.52)	
1.07	
(0.78-1.47)	 19/134	
1.10	
(0.67-1.81)	
1.01	
(0.60-1.68)	 12/70	
1.27	
(0.69-2.34)	
1.21	
(0.66-2.22)	
P	for	Interaction	 	 	 0.64	 0.81	 	 0.64	 0.81	 	 0.64	 0.81	
Race	†	 	 	 	 	 	 	 	 	 	 	
White	 153/1313	 133/989	 1.03	(0.82-1.30)	
1.01	
(0.80-1.28)	 39/278	
1.14	
(0.80-1.62)	
1.05	
(0.73-1.50)	 18/139	
0.94	
(0.58-1.54)	
0.93	
(0.57-1.52)	
Non-white	 8/101	 5/90	 0.58	(0.19-1.78)	
0.54	
(0.17-1.64)	 1/25	
0.41	
(0.05-3.25)	
0.38	
(0.05-3.07)	 0/10	 NA	 NA	
P	for	Interaction	 	 	 0.037	 0.033	 	 0.037	 0.033	 	 0.037	 0.033	
Previous	CVD	 	 	 	 	 	 	 	 	 	 	
None		‡	 132/1470	 100/1078	 0.97	(0.75-1.26)	
0.99	
(0.76-1.29)	 28/291	
0.98	
(0.65-1.48)	
0.93	
(0.61-1.41)	 16/146	
1.11	
(0.66-1.87)	
1.13	
(0.67-1.90)	
Yes	 58/336	 49/306	 0.76	(0.52-1.11)	
0.77	
(0.53-1.14)	 16/92	
1.00	
(0.58-1.74)	
0.99	
(0.57-1.73)	 6/45	
0.65	
(0.28-1.52)	
0.67	
(0.29-1.55)	
P	for	Interaction	 	 	 0.78	 0.74	 	 0.78	 0.74	 	 0.78	 0.74	
Thyroxine	use	at	BL	 	 	 	 	 	 	 	 	 	 	
None	 190/1806	 149/1384	 0.92	(0.74-1.14)	
0.91	
(0.74-1.14)	 44/383	
1.02	
(0.73-1.41)	
0.95	
(0.68-1.33)	 22/191	
0.94	
(0.61-1.47)	
0.93	
(0.60-1.45)	
Yes	 10/105	 13/135	 0.98	(0.43-2.24)	
0.95	
(0.40-2.26)	 3/73	
0.45	
(0.12-1.63)	
0.53	
(0.14-1.95)	 11/63	
1.87	
(0.79-4.41)	
1.95	
(0.81-4.74)	
P	for	Interaction	 	 	 0.37	 0.31	 	 0.37	 0.31	 	 0.37	 0.31	
	
Abbreviations:	AF,	atrial	fibrillation;	BL,	baseline;	CI,	confidence	interval;	CVD,	cardiovascular	disease;	E,	events;	HR,	hazard	ratio;		
NA,	data	not	applicable;	P,	participants;	TSH,	thyroid-stimulating	hormone	
*	The	TSH	category	3.50-4.49mIU/l	was	the	reference	category	
†	African	Americans,	Hispanics,	Asian,	and	others	were	considered	as	non-white	population.	Data	on	race	were	missing	for	all	participants	of	the	SHIP	study,	the	InChianti	
Study,	and	the	PROSPER	Study,	67	participants	of	the	Rotterdam	Study	and	44	of	the	EPIC-Norfolk	Study.	
‡	Previous	cardiovascular	was	defined	as	a	history	of	stroke,	transient	ischemic	attack,	myocardial	infarction,	angina	pectoris,	coronary	angioplasty,	bypass	surgery.	Participants	
without	any	of	these	events	were	considered	having	no	previous	cardiovascular	disease.	
§	Adjusted	for	age,	sex,	systolic	blood	pressure,	current	and	former	smoking,	diabetes,	total	cholesterol	and	prevalent	cardiovascular	disease.	
	
	
	 	
Supplemental	Table	9.	Sensitivity	Analyses	of	the	Association	between	Quartiles	of	Free	Thyroxine	within	the	Reference	Range	and	the	Risk	of	Atrial	Fibrillation	
fT4	quartile	 First	quartile	 	
Second	
quartile	 	
Third	
quartile	 	
Fourth	
quartile	
	 	
	 Events	/	Participants	
HR	
(95%	CI)	
Events	/	
Participants	
HR	
(95%	CI)	
Events	/	
Participants	
HR	
(95%	CI)	
Events	/	
Participants	
HR	
(95%	CI)	
P	for	
trend	
Main	analysis		
(age-	and	sex-adjusted)	 371/5642	 ref.	 390/4989	
1.17	
(1.02-1.35)	 438/5272	
1.25	
(1.09-1.43)	 474/5018	
1.45	
(1.26-1.66)	 £0.001	
Excluding	users	of	amiodarone	and	a	
study	with	missing	relevant	data	*	 367/5245	 ref.	 389/4817	
1.17	
(1.02-1.35)	 433/5000	
1.24	
(1.08-1.42)	 463/4793	
1.42	
(1.24-1.63)	 £0.001	
Excluding	thyroid	medication	use		
at	BL	and/or	FUP	and	studies	with	
missing	relevant	data	†	
211/2345	 Ref.	 238/2063	 1.17	(0.97-1.40)	 218/2115	
1.16	
(0.96-1.40)	 250/2063	
1.37	
(1.14-1.64)	 0.002	
Abbreviations:	BL,	baseline;	CI,	confidence	interval;	fT4;	free	thyroxine;	FUP,	follow-up;	HR,	hazard	ratio.	
*	A	total	of	1,066	participants	were	excluded	for	this	sensitivity	analysis	of	the	association	between	fT4	and	atrial	fibrillation:	1	participant	who	took	amiodarone	in	the	CHS;	1	
in	the	MrOS;	57	in	the	Bari	Study;	3	in	the	InChianti	Study;	1	in	the	EPIC-Norfolk	Study,	and	all	1003	participants	in	the	Busselton	Health	Study,	in	which	information	on	
amiodarone	use	was	not	available.	
†	A	total	of	12,335	participants	were	excluded	for	this	sensitivity	analysis	of	the	association	between	fT4	and	atrial	fibrillation:	139	participants	in	the	CHS;	11	in	the	MrOS;	15	in	
the	Bari	Study;	3	in	the	Leiden	85+	Study;	156	in	the	SHIP;	13	in	the	InChianti	Study;	2	in	the	PROSPER	Study;	and	9	in	the	Busselton	Health	Study;	and	all	10,745	participants	in	
the	EPIC-Norfolk	Study	and	all	1,242	participants	in	the	Rotterdam	Study,	because	information	on	thyroid	medication	use	during	follow-up	was	not	available	in	these	studies.		
	 	
Supplemental	Table	10.	Stratified	Analyses	for	the	Association	between	Quartiles	of	Free	Thyroxine	within	the	Reference	Range	and	the	Risk	of	Atrial	Fibrillation	*	
fT4	Quantile	 First	
Quartile	
	 	 Second	
Quartile	
	 	 Third	
Quartile	
	 	 Fourth	
Quartile	
	 	
Variable	 Events/		Persons	
HR	
(95%	CI)	
HR	
(95%CI)	
Events/		
Persons	
HR	
(95%	CI)	
HR	
(95%	CI)	
Events/		
Persons	
HR	
(95%	CI)	
HR	
(95%	CI)	
Events/		
Persons	
HR	
(95%	CI)	
HR	
(95%	CI)	
	 	 Age/Sex	Adj	 Multivariate	Model	§	
	 Age/Sex	Adj	 Multivariate	Model	§	
	 Age/Sex	Adj	 Multivariate	Model	§	
	 Age/Sex	Adj	 Multivariate	Model	§	
Total	
Population	 371/5642	 ref.	 ref.	 390/4989	
1.17	
(1.02-1.35)	
1.16	
(1.00-1.33)	 438/5272	
1.25	
(1.09-1.43)	
1.19	
(1.04-1.37)	 474/5018	
1.45	
(1.26-1.66)	
1.39	
(1.22-1.60)	
Age,	y	 	 	 	 	 	 	 	 	 	 	 	 	
18-64	 62/3146	 ref.	 ref.	 47/2704	 0.85	(0.58-1.24)	
0.85	
(0.58-1.24)	 73/2818	
1.26	
(0.90-1.77)	
1.25	
(0.89-1.76)	 81/2561	
1.54	
(1.10-2.14)	
1.53	
(1.09-2.14)	
≥65	 309/2496	 ref.	 ref.	 343/2285	 1.23	(1.05-1.43)	
1.20	
(1.03-1.40)	 365/2454	
1.23	
(1.06-1.43)	
1.17	
(1.00-1.37)	 393/2457	
1.46	
(1.25-1.69)	
1.39	
(1.20-1.62)	
P	for	Trend	 	 	 	 	 0.16	 0.15	 	 0.16	 0.15	 	 0.16	 0.15	
Sex	 	 	 	 	 	 	 	 	 	 	 	 	
Women	 170/3123	 ref.	 ref.	 169/2596	 1.13	(0.91-1.39)	
1.12	
(0.90-1.39)	 215/2700	
1.41		
(1.15-1.72)	
1.33	
(1.09-1.64)	 214/2269	
1.56	
(1.27-1.90)	
1.51	
(1.23-1.85)	
Men	 201/2519	 ref.	 ref.	 221/2393	 1.20	(0.99-1.46)	
1.18	
(0.97-1.43)	 223/2572	
1.12	
(0.93-1.36)	
1.07	
(0.88-1.30)	 260/2749	
1.36	
(1.13-1.64)	
1.30	
(1.08-1.56)	
P	for	Interaction	 	 	 	 	 0.16	 0.18	 	 0.16	 0.18	 	 0.16	 0.18	
Race	†	 	 	 	 	 	 	 	 	 	 	 	 	
White	 311/4405	 ref.	 ref.	 333/3848	 1.17	(1.00-1.36)	
1.16	
(0.99-1.35)	 383/4072	
1.29	
(1.11-1.50)	
1.23	
(1.06-1.44)	 414/3876	
1.48	
(1.28-1.71)	
1.41	
(1.22-1.64)	
Non-white	 27/208	 ref.	 ref.	 27/141	 1.42	(0.83-2.43)	
1.46	
(0.84-2.53)	 32/179	
1.36	
(0.81-2.27)	
1.43	
(0.85-2.42)	 30/172	
1.61	
(0.96-2.72)	
1.77	
(1.04-3.01)	
P	for	Interaction	 	 	 	 	 0.93	 0.98	 	 0.93	 0.98	 	 0.93	 0.98	
Previous	CVD		 	 	 	 	 	 	 	 	 	 	 	 	
None	‡	 267/5089	 ref.	 ref.	 288/4449	 1.20	(1.02-1.42)	
1.17	
(0.99-1.39)	 324/4670	
1.32	
(1.12-1.55)	
1.26	
(1.07-1.49)	 362/4394	
1.57	
(1.34-1.84)	
1.52	
(1.29-1.78)	
Yes	 104/553	 ref.	 ref.	 102/540	 1.06	(0.80-1.39)	
1.07	
(0.81-1.41)	 114/602	
1.01	
(0.77-1.32)	
1.01	
(0.77-1.32)	 112/624	
1.05	
(0.81-1.38)	
1.05	
(0.80-1.37)	
P	for	Interaction	 	 	 	 	 0.068	 0.084	 	 0.068	 0.084	 	 0.068	 0.084	
Thyroxine	use	at	
BL	 	 	 	 	 	 	 	 	 	 	 	 	
None	 371/5655	 ref.	 ref.	 414/5122	 1.16	(1.01-1.34)	
1.15	
(1.00-1.32)	 431/5335	
1.28	
(1.11-1.47)	
1.22	
(1.06-1.41)	 457/4809	
1.43	
(1.25-1.64)	
1.38	
(1.20-1.59)	
Yes	||	 9/69	 ref.	 ref.	 13/78	 1.69	(0.70-4-05)	
1.66	
(0.69-3.98)	 16/120	
1.59	
(0.68-3.70)	
1.68	
(0.72-3.95)	 30/275	
1.41	
(0.65-3.08)	
1.48	
(0.67-3.26)	
P	for	Interaction	 	 	 	 	 0.53	 0.58	 	 0.53	 0.58	 	 0.53	 0.58	
Abbreviations:	Adj,	adjusted;	AF,	atrial	fibrillation;	BL,	baseline;	CI,	confidence	interval;	CVD,	cardiovascular	disease;	E,	events;	HR,	hazard	ratio;	NA,	data	not	applicable;	P,	
participants;	ref.,	reference;	TSH,	thyroid-stimulating	hormone	
*	This	analysis	was	restricted	to	normal	thyroid	function,	i.e.	TSH	and	thyroxine	in	the	reference	range.	From	the	overall	sample	a	total	of	9164	participants	were	excluded	for	
this	analysis	with	either	missing	measurements	of	fT4	or	thyroid	function	outside	the	reference	range.	479	participants	of	the	Cardiovascular	Health	Study,	59	of	the	
Osteoporotic	Fractures	in	Men	Study,	32	of	the	Bari	Study,	137	of	the	Leiden	85+	Study,	125	of	the	Study	of	Health	in	Pomerania,	42	of	the	InChianti	Study,	365	of	the	
Rotterdam	Study,	897	of	the	EPIC-Norfolk	Study,	and	57	of	the	Busselton	Health	Study.	In	participants	of	the	Health	ABC	Study,	fT4	was	measured	only	in	TSH	³	7.0	mIU/L;	
therefore	all	2346	participants	were	excluded	for	this	analysis.	In	the	PROSPER	Study,	fT4	was	measured	only	in	participants	with	TSH	<0.45mIU/l	or	TSH	³4.5mIU/l;	therefore,	
4625	participants	were	excluded	from	this	analysis.	
†	African	Americans,	Hispanics,	Asian,	and	others	were	considered	as	non-white	population.	Data	on	race	were	missing	for	all	participants	of	the	SHIP	study,	the	InChianti	
Study,	and	the	PROSPER	Study,	51	participants	of	the	Rotterdam	Study	and	37	of	the	EPIC-Norfolk	Study.	
‡	Previous	cardiovascular	was	defined	as	a	history	of	stroke,	transient	ischemic	attack,	myocardial	infarction,	angina	pectoris,	coronary	angioplasty,	bypass	surgery.	Participants	
without	any	of	these	events	were	considered	having	no	previous	cardiovascular	disease.	
§	Adjusted	for	age,	sex,	systolic	blood	pressure,	current	and	former	smoking,	diabetes,	total	cholesterol	and	prevalent	cardiovascular	disease.	
||	542	participants	with	available	measurement	of	fT4	and	normal	thyroid	function	were	on	thyroxine	at	baseline:	167	participants	of	the	CHS,	33	of	the	MrO2,	6	of	the	Bari,	5	
of	the	Leiden	85+	Study,	76	of	SHIP,	11	of	the	InChianti	Study,	9	of	the	Rotterdam	Study,	8	of	the	PROSPER	Study,	224	of	the	EPIC-Norfolk	Study,	and	3	of	the	Busselton	Health	
Study.	
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Figure	Legends	
Supplemental	Figure	1.	Selection	of	the	final	study	population	for	the	individual	participant	data	analysis.		
Abbreviations:	AF,	atrial	fibrillation;	fT4,	free	thyroxine;	TSH,	thyroid	stimulating	hormone.	
Supplemental	Figure	2.	Study	flow	diagram.	Studies	evaluated	for	inclusion	in	the	IPD	analysis,	adapted	from	
PRISMA-IPD	Statement	Flow	Diagram.3		Abbreviations:	IPD,	individual	participant	data	
*	Until	July	27,	2016	
†	from	prospective	cohorts	participating	in	the	international	Thyroid	Studies	Collaboration	that	had	prospective	
data	on	atrial	fibrillation	outcomes	
‡	List	of	excluded	full	text	articles	in	Supplemental	Table	2	
§Two	articles	retrieved	through	database	searching	included	the	same	population	of	the	Cardiovascular	Health	
Study	4,5	
||	Data	on	1759	euthyroid	and	subclinically	hypothyroid	participants	from	the	Framingham	Heart	Study	6	were	
not	provided	free	of	charge.		Among	the	8740	participants	included	in	the	Rotterdam	Study,7	data	of	the	1426	
participants	included	in	the	Rotterdam	Study	Cohort	I	that	had	been	previously	published	8	were	provided,	
whereas	data	on	7314	participants	of	the	Rotterdam	Study	Cohorts	II	and	III	were	not	provided.	
#	Chaker	and	colleagues	reported	aggregate	data	of	the	Rotterdam	Study	Cohorts	I,	II,	and	III,	therefore	the	
individual	participant	data	of	Rotterdam	Cohort	I	(that	were	included	in	our	main	analysis)	were	excluded	for	
the	sensitivity	analysis	including	the	aggregate	data.7	
Supplemental	Figure	3.	Restricted	cubic	spline	plot	for	the	association	between	continuous	concentrations	of	
thyroid	stimulating	hormone	and	atrial	fibrillation.	The	p-value	for	a	non-linear	trend	was	0.067.	Abbreviations:	
TSH,	thyroid	stimulating	hormone.		
Supplemental	Figure	4.	Restricted	cubic	spline	plot	for	the	association	between	continuous	concentrations	of	
free	thyroxine	within	the	reference	range	and	atrial	fibrillation.	The	p-value	for	a	non-linear	trend	was	£0.001.	
Abbreviations:	fT4,	free	thyroxine;	SD,	standard	deviation.		
Supplemental	Figure	5.	Funnel	plot	for	the	association	between	free	thyroxine	within	the	reference	range	and	
atrial	fibrillation.	Estimates	of	the	highest	fT4	quartile	compared	to	the	lowest	fT4	quartile	were	considered.	
Abbreviations:	fT4,	free	thyroxine;	SE,	standard	error.	
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